<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866619</url>
  </required_header>
  <id_info>
    <org_study_id>110021</org_study_id>
    <secondary_id>2012-005716-26</secondary_id>
    <nct_id>NCT00866619</nct_id>
  </id_info>
  <brief_title>Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa</brief_title>
  <official_title>Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The PATH Malaria Vaccine Initiative (MVI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this observer-blind study is to gather key efficacy, safety, and
      immunogenicity information on GSK's candidate malaria vaccine in infants and children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol posting document has been updated due to a protocol amendment dated 23 January
      2012. An analysis time point has been added at Month 20. No changes have been made to the
      protocol endpoints or statistical methods but protocol endpoints will be analysed on data
      collected up to Month 20 once these data are available. The rationale is to have the full
      scope of protocol defined efficacy and safety endpoints related to a primary schedule without
      booster in both age categories followed up for 20 months earlier than at the initially
      planned study end time point (Visit 34 or Month 32 time point).

      The protocol posting document was updated due to a protocol amendment dated 10 December 2010
      to extend the study until December 2013 for all enrolled subjects (interval: Nov 2013-Jan
      2014). Including the extension, the mean follow-up time for subjects from 5-17 months will be
      during 49 months post dose 1 (range: 41-55), while for subjects from 6-12 weeks, it will be
      during 41 months post dose 1 (range: 32-48). This study is double-blind during the first part
      and single-blind during the extension part. An analysis will be conducted at the end of the
      extension including an evaluation of safety and efficacy against clinical malaria, severe
      malaria and prevalent parasitemia.

      The protocol posting document has been updated following the posting of results of the study
      (January 2015): The study remained double-blind until the end of the extension phase, and the
      analyses of Month 32 (initial end of study now becoming end of the first part of the study or
      primary study phase) and of the extension phase were conducted together.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2009</start_date>
  <completion_date type="Actual">January 31, 2014</completion_date>
  <primary_completion_date type="Actual">March 1, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of First or Only Clinical Episode of Plasmodium Falciparum (P. Falciparum) Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)</measure>
    <time_frame>From Month 2.5 to Month 14</time_frame>
    <description>A CPFMI-PCD was defined as an episode of malaria for which P. falciparum asexual parasitemia was greater than (&gt;) 5000 parasites per microliter (µL) accompanied by the presence of fever [axillary temperature greater than or equal to (≥) 37.5°C] at the time of presentation AND occurring in a child who is unwell and brought for treatment to a healthcare facility OR a case of malaria meeting the primary case definition of severe malaria disease. The time to first or only CPFMI-PCD is expressed in terms of rate of first or only CPFMI (RfoCPFMI), that is person-year rate in each group (n/T). Analysis for this outcome was solely performed on subjects in the 5-17 months age category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of First or Only Clinical Episode of P. Falciparum Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)</measure>
    <time_frame>From Month 2.5 to Month 14</time_frame>
    <description>A CPFMI-PCD was defined as an episode of malaria for which P. falciparum asexual parasitemia &gt; 5000 parasites/µL was accompanied by the presence of fever (axillary temperature ≥ 37.5°C) at the time of presentation AND occurring in a child who is unwell and brought for treatment to a healthcare facility OR a case of malaria meeting the primary case definition of severe malaria disease. The time to first or only CPFMI-PCD is expressed in terms of rate of first or only CPFMI (RfoCPFMI), that is, person-year rate in each group (n/T). Analysis for this outcome was solely performed on subjects in the 6-12 weeks (6-12W) age category.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of P. Falciparum Clinical Malaria Infection (CPFMI) of PCD and of Secondary Case Definitions (SCD) 1, SCD 2 and SCD 3</measure>
    <time_frame>From Month 2.5 to Month 14</time_frame>
    <description>PCD=malaria episode with P. falciparum asexual parasitemia (PFAP) &gt; 5000 parasites/µL accompanied by fever and occurring in a child unwell brought for treatment to a healthcare facility or a case of malaria meeting the PCD of severe malaria disease. SCD1=malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. SCD2=malaria episode with PFAP &gt; 500 parasites/μL and fever at time of presentation in a subject unwell brought for treatment to a healthcare facility. SCD3=malaria episode with PFAP &gt; 20.000 parasites/μL and fever at time of presentation in a subject unwell and brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD, Overall and by Center</measure>
    <time_frame>From Month 2.5 to Month 20</time_frame>
    <description>PCD = malaria episode with PFAP &gt; 5000 parasites/µL accompanied by fever and occurring in a child unwell brought for treatment to a healthcare facility or a case of malaria meeting the PCD of severe malaria disease (see below endpoints on severe malaria for details). Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are by center and across centers, and are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of SCD1, SCD2 and SCD3 (Overall)</measure>
    <time_frame>From Month 2.5 to Month 20</time_frame>
    <description>SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. SCD2 = malaria episode with PFAP &gt; 500 parasites/μL and fever at time of presentation in a subject unwell brought for treatment to a healthcare facility. SCD3 = malaria episode with PFAP &gt; 20.000 parasites/μL and fever at time of presentation in a subject unwell and brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are across centers, and are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Centers and Across Centers</measure>
    <time_frame>From Month 2.5 up to study End (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
    <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented by center and across centers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Secondary Case Definition 1 (SCD1), Across Centers</measure>
    <time_frame>From Month 2.5 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
    <description>CPFMI of SCD1 = malaria episode with PFAP &gt;0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented across centers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD) and Secondary Case Definition 1 (SCD1), Across Centers</measure>
    <time_frame>From Booster at Month 20 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
    <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. CPFMI of SCD1 = malaria episode with PFAP &gt;0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented across centers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD and SCD1, Across Centers</measure>
    <time_frame>From Month 33 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
    <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. CPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented across centers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD, by Center and Across Centers</measure>
    <time_frame>From Month 2.5 to Month 32</time_frame>
    <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented by center and across centers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Secondary Case Definition 1 (SCD1)</measure>
    <time_frame>From Month 2.5 to Month 32</time_frame>
    <description>CPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD) and Secondary Case Definition 1 (SCD1)</measure>
    <time_frame>From Booster at Month 20 up to Month 32</time_frame>
    <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. CPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Severe PFMI (SPFMI) of PCD, SCD1, SCD2 and SCD3, Across Centers</measure>
    <time_frame>From Month 2.5 up to the time when 250 subjects were diagnosed with severe malaria of PCD, SCD1, SCD2 and SCD3 (up to the Month 14 time point for each age category or date of booster dose, whichever occurred first)</time_frame>
    <description>SPFMI of PCD = PFMI &gt; 5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI &gt;5000 parasites/μL and with one or more severity marker. SPFMI of SCD2 = PFMI &gt;0 with one or more severity marker and without co-morbidity diagnosis. SPFMI of SCD3 = PFMI &gt;5000 parasites/μL, with one or more severity marker, and without co-morbidity or HIV. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia &lt; 2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l &lt; 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72 h of admission; gastroenteritis with dehydration. Analysis was performed in a pooled manner across age categories. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1</measure>
    <time_frame>From Month 2.5 to Month 14</time_frame>
    <description>SPFMI of PCD = PFMI&gt;5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72h of admission; gastroenteritis with dehydration. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1</measure>
    <time_frame>From Month 2.5 to Month 20 at Booster</time_frame>
    <description>SPFMI of PCD = PFMI&gt;5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72h of admission; gastroenteritis with dehydration. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1</measure>
    <time_frame>From Month 2.5, from Month 20(booster), from Month 33 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17M age category and of 38 months post-Dose 1 for 6-12W age category) and from Month 2.5 to Month 32 and from Month 20 to Month 32</time_frame>
    <description>SPFMI of PCD = PFMI &gt;5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI &gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72 h of admission; gastroenteritis with dehydration. SPFMI of SCD1 = PFMI &gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Incident Severe Anaemia (ISA) and Malaria Hospitalization (MH) for Case Definitions (CD) Considered</measure>
    <time_frame>From Month 2.5 to Month 20</time_frame>
    <description>CD considered were CD1 for ISA and CD1 and CD2 for MH. ISA of CD1 was defined as a documented hemoglobin &lt; 5.0 g/dL identified at clinical presentation to morbidity surveillance system in association with a P. falciparum parasitemia &gt; 5000 parasites/μL. MH of CD1 was defined as a medical hospitalization with confirmed P. falciparum &gt; 5000 parasites/μL. MH of CD2 was defined as a hospitalization which, in the judgment of the principal investigator, P. falciparum infection was the sole or a major contributing factor to the presentation. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Incident Severe Anaemia (ISA), Malaria Hospitalization (MH) and Fatal Malaria (FM) for Case Definitions (CD) Considered</measure>
    <time_frame>From Month 2.5 to up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
    <description>ISA CD considered were CD1, CD2 and CD3 (definitions mentioned in the previous outcome measure). MH CD considered were CD1 and CD2 (definitions mentioned in the previous outcome measure).FM CD considered were primary CD (PCD) and sedondary CDs 1 and 4 (SCD1 and SCD4). FM of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease with a fatal outcome. FM of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease with a fatal outcome. FM of SCD4 was defined as a fatal case associated with International Classification Disease (ICD10) codes B50, B53 and/or B54. Code B50 corresponds to P. falciparum malaria including mixed infections of P. falciparum with any other Plasmodium species; Code B53 corresponds to other parasitologically confirmed malaria; Code B54 corresponds to unspecified malaria including clinically diagnosed malaria without parasitological confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Incident Severe Anaemia (ISA), Malaria Hospitalization (MH) and Fatal Malaria (FM) for Case Definitions (CD) Considered</measure>
    <time_frame>From Month 2.5 to Month 32</time_frame>
    <description>ISA CD considered were CD1, CD2 and CD3 (definitions mentioned in the previous outcome measure). MH CD considered were CD1 and CD2 (definitions mentioned in the previous outcome measure).FM CD considered were primary CD (PCD) and sedondary CDs 1 and 4 (SCD1 and SCD4). FM of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease with a fatal outcome. FM of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease with a fatal outcome. FM of SCD4 was defined as a fatal case associated with International Classification Disease (ICD10) codes B50, B53 and/or B54. Code B50 corresponds to P. falciparum malaria including mixed infections of P. falciparum with any other Plasmodium species; Code B53 corresponds to other parasitologically confirmed malaria; Code B54 corresponds to unspecified malaria including clinically diagnosed malaria without parasitological confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Prevalent Parasitemia, Prevalent Gametocytemia and Prevalent Severe and Moderate Anemia</measure>
    <time_frame>At Month 20 (Booster)</time_frame>
    <description>Prevalent parasitemia (PP) was defined as a documented P. falciparum asexual parasite density &gt; 0 identified at timing of assessment. Prevalent gametocytemia (PG) was defined as a documented P. falciparum gametocyte density &gt; 0 identified at a cross sectional survey. Prevalent severe anemia (PSA) was defined as a documented hemoglobin &lt; 5.0 g/dL identified at timing of assessment. Prevalent moderate anemia (PMA) was defined as a documented hemoglobin &lt; 8.0 g/dL identified at at timing of assessment. Results presented are uncorrected for the double enrollment of one subject receiving RTS,S/AS01.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Prevalent Parasitemia and Prevalent Severe and Moderate Anemia</measure>
    <time_frame>At Months 32, 44, at study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category) (early and late)</time_frame>
    <description>Prevalent parasitemia (PP) was defined as a documented P. falciparum asexual parasite density &gt; 0 identified at timing of assessment. Prevalent severe anemia (PSA) was defined as a documented hemoglobin &lt; 5.0 g/dL identified at timing of assessment. Prevalent moderate anemia (PMA) was defined as a documented hemoglobin &lt; 8.0 g/dL identified at timing of assessment. Analysis was performed on subjects aged 5-17 months at enrollment. Study End (Early) corresponds to children whose Month 32 visit took place after 30 June 2012 and who had one cross-sectional visit at study end. These children's last study visit was relatively earlier, with a median follow-up time of 14 months post Month 32. Study End (Late) corresponds to children whose Month 32 visit took place before (and including) 30 June 2012, and who had 2 cross-sectional visits after Month 32. These children's last study visit was relatively later, with a median follow-up time of 17 months post Month 32).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Pneumonia, All-cause Hospitalization and Sepsis, as Per Case Definitions Assessed</measure>
    <time_frame>From Month 2.5 to Month 20</time_frame>
    <description>Pneumonia case definitions assessed are PCD and SCD 1, 2 and 3. Pneumonia of PCD was defined as cough or difficulty breathing AND tachypnea (≥ 50 breaths per minute &lt; 1 year, ≥ 40 breaths per minute ≥ 1year) AND lower chest wall indrawing. Pneumonia of SCD1 was defined as pneumonia of PCD accompanied by chest X-ray (CXR) consolidation or pleural effusion on x-ray taken within 72 h of admission. Pneumonia of SCD2 was defined as pneumonia of PCD accompanied by consolidation or pleural effusion or other infiltrates on a chest x-ray taken within 72 h of admission. Pneumonia of SCD3 was defined as pneumonia of PCD accompanied by an oxygen saturation &lt; 90%. All-cause hospitalization of PCD was defined as a medical hospitalization of any cause (excludes planned admissions for medical investigation/care or elective surgery and trauma). Sepsis cases were defined as a child with positive blood culture (CD1) or salmonella blood culture (CD2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Fatal Malaria (FM) and All-cause Mortality (ACM) as Per Case Definitions Assessed</measure>
    <time_frame>From Month 2.5 to Month 20</time_frame>
    <description>Fatal malaria case definitions assessed were PCD and SCD1. Fatal malaria of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease (defined in a previous outcome measure) with a fatal outcome. Fatal malaria of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease (defined previously) with a fatal outcome. All-cause mortality case definitions assessed were the case definitions (CD) 1 and 2. All-cause mortality of CD1 was defined as a fatality (of any cause) (including mortality in the community and in hospital). All-cause mortality of CD2 was defined as a fatality (medical cause) (including mortality in the community and in hospital), at the exclusion of trauma which may be diagnosed by verbal autopsy. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Pneumonia, All-cause Hospitalization/Mortality and Sepsis, as Per Case Definitions Assessed</measure>
    <time_frame>From Month 2.5 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
    <description>Pneumonia of PCD was defined as cough or difficulty breathing (on history) AND tachypnea (&gt;= 50 breaths per minute &lt; 1 year, &gt;= 40 breaths per minute &gt;= 1year) AND lower chest wall indrawing,SCD1 was defined as pneumonia of PCD accompanied by chest X-ray (CXR) consolidation or pleural effusion on x-ray taken within 72 h of admission,SCD2 was defined as pneumonia of PCD accompanied by consolidation or pleural effusion or other infiltrates on a chest x-ray taken within 72 h of admission,SCD3 was defined as pneumonia of PCD accompanied by an oxygen saturation less than 90%.All-cause hospitalization of PCD was defined as a medical hospitalization of any cause (excluding planned admissions for medical investigation/care or elective surgery and trauma).All-cause mortality of CD1 was defined as a fatality (of any cause),of CD2 defined as a fatality (medical cause).Sepsis of CD1 was defined as a child with positive blood culture;CD2 defined as a child with positive salmonella blood culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Blood Transfusion, as Per Case Definition Assessed</measure>
    <time_frame>From Month 2.5 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
    <description>Blood transfusion case definition assessed was the case definition 1 (CD1). Blood transfusion of CD1 was defined as a child with inpatient admission with documented blood transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Gender and Overall</measure>
    <time_frame>From Month 2.5 to Month 32</time_frame>
    <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T). Analysis was performed on subjects aged 5-17 months and 6-12 weeks at enrollment. Results were presented by gender and overall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height, Weight and Mid Upper Arm Circumference for Age Z-score (HAZ, WAZ and MUACZ)</measure>
    <time_frame>At Month 20 (Booster)</time_frame>
    <description>Anthropometry consisted of length/height for age z-score [HAZ] (children &lt; 2 years length measure and children ≥ 2 years standing height measure), weight for age z-score [WAZ] and mid-upper arm circumference for age z-score [MUACZ] measurements, where a HAZ &lt; -1,5 z-score, indicates growth deficit, while a HAZ between -1,0 and ± 1,0 z-score, indicates normal height. A WAZ ≤ -3 z-score indicates a very low weight for age, a WAZ &gt; -3 and ≤ -2 z-score indicates a low weight for age, a WAZ &gt; - 2 z-score indicates normal weight. A MUACZ &lt; -2 z-score indicates children that are wasted, a MUACZ &lt; - 3 z-score indicates severely wasted children.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height, Weight and Mid Upper Arm Circumference for Age Z-score (HAZ, WAZ and MUACZ)</measure>
    <time_frame>At Months 32, 44, at study end (early and late) (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
    <description>Anthropometry consisted of length/height for age z-score [HAZ] (children &lt; 2 years length measure and children ≥ 2 years standing height measure), weight for age z-score [WAZ] and mid-upper arm circumference for age z-score [MUACZ] measurements, where a HAZ &lt; -1,5 z-score, indicates growth deficit, while a HAZ between -1,0 and ± 1,0 z-score, indicates normal height. A WAZ ≤ -3 z-score indicates a very low weight for age, a WAZ &gt; -3 and ≤ -2 z-score indicates a low weight for age, a WAZ &gt; - 2 z-score indicates normal weight. A MUACZ &lt; -2 z-score indicates children that are wasted, a MUACZ &lt; - 3 z-score indicates severely wasted children. Note: The early study end refers to children whose last visit in the primary study phase (Month 32) was after 30 June 2012 and who by protocol had one cross-sectional study end and to late study end refers to children whose last visit in the primary study phase (Month 32) was after 30 June 2012 and who by protocol had one cross-sectional study end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Plasmodium Falciparum Circumsporozoite (Anti-CS)</measure>
    <time_frame>At Day 0 and at Month 3</time_frame>
    <description>Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were assessed for the first 200 subjects enrolled in each study center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS)</measure>
    <time_frame>At Day 0 and at Month 3</time_frame>
    <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were assessed for the first 200 HIV-infected subjects enrolled in each study center. HIV infection was confirmed if present at screening or identified by morbidity surveillance, not infection confirmed by antibody testing after 18 months of age or by PCR, by the time of the analysis of results up to the Month 14 time point for the respective 5-17 months and 6-12 weeks age categories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS)</measure>
    <time_frame>At Months 20, 21 and 32</time_frame>
    <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS)</measure>
    <time_frame>At Month 44 and at study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
    <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results for this endpoint were assessed for Agogo, Lilongwe and Siaya sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS), by Tertile</measure>
    <time_frame>At Month 3</time_frame>
    <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were presented by tertiles of anti-CS responses in the first 200 participants per site, based on subjects assessed for vaccine efficacy results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Tertile</measure>
    <time_frame>From Month 2.5 to Month 32</time_frame>
    <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T). RaCPFMI was calculated by tertile of anti-CS response post primary vaccination pooled across sites, on subjects in GSK257049-Menjugate Groups (5-17M; 6-12W) and Comparator Groups (5-17M; 6-12W), taking into account the first 200 participants per site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS), by Tertile</measure>
    <time_frame>At Month 21</time_frame>
    <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were presented by tertiles of anti-CS responses in the first 200 participants per site, based on subjects assessed for vaccine efficacy results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Tertile</measure>
    <time_frame>From Booster at Month 20 to Month 32</time_frame>
    <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T). RaCPFMI was calculated by tertile of anti-CS response post booster vaccination pooled across sites, on subjects in R3R (5-17M; 6-12W) (or R3R below) and C3C (5-17M; 6-12W) (or C3C below) groups taking into account the first 200 participants per site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Hepatitis B Surface Antigen (Anti-HBs)</measure>
    <time_frame>At Day 0 and at Month 3</time_frame>
    <description>Antibody concentrations assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU/mL). The seropositivity and seroprotection cut-offs were ≥ 10 and 100 mIU/mL, respectively. Results were assessed for the first 200 subjects in each center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Hepatitis B Surface Antigen</measure>
    <time_frame>At Day 0 and at Month 3</time_frame>
    <description>Antibody concentrations as assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in mIU/mL. The seropositivity and seroprotection cut-offs were ≥ 10 and 100 mIU/mL, respectively. Results were assessed for the first 200 HIV-infected subjects enrolled in each study center. HIV infection was confirmed if present at screening or identified by morbidity surveillance, not infection confirmed by antibody testing after 18 months of age or by PCR, by the time of the analysis of results up to the Month 14 time point for the respective 5-17 months and 6-12 weeks age categories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Hepatitis B Surface Antigen (Anti-HBs)</measure>
    <time_frame>At Months 20 and 21</time_frame>
    <description>Antibody concentrations as assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in mIU/mL. The seropositivity and seroprotection cut-offs were ≥ 6.2 and 100 mIU/mL, respectively. Results were assessed for the first 200 subjects in each center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Titers Against Poliomyelitis (Anti-polio) Type 1, 2 and 3</measure>
    <time_frame>At Day 0 and at Month 3</time_frame>
    <description>Anti-Polio 1, 2 and 3 antibody titers were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was an antibody titer ≥ 1:8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-primary vaccination period following each dose and across doses</time_frame>
    <description>Assessed solicited local symptoms included pain, redness and swelling. Any = the incidence of a particular symptom, regardless of intensity grade. Grade 3 pain = cried when limb was moved, spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-primary vaccination period following each dose and across doses</time_frame>
    <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-booster vaccination period</time_frame>
    <description>Assessed solicited local symptoms included pain, redness and swelling. Any = the incidence of a particular symptom, regardless of intensity grade. Grade 3 pain = cried when limb was moved, spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-booster vaccination period</time_frame>
    <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Doses With Seizures by Diagnostic Certainty Level</measure>
    <time_frame>During the 7-day (Days 0-6) post-booster vaccination period, at Month 20 + 7 Day (Days 0-6)</time_frame>
    <description>Diagnostic certainty levels included: Level 1- Witnessed sudden loss of consciousness and generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations; Level 2- History of unconsciousness and generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations; Level 3- History of unconsciousness and other generalized motor manifestations; Level 4- Reported generalized convulsive seizure with insufficient evidence to meet the case definition; Level 5- Not a case of generalized convulsive seizure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Mucocutaneous Changes (All Levels)</measure>
    <time_frame>During the 30-day (Days 0-29) post-booster vaccination</time_frame>
    <description>Levels of mucocutaneous changes reported were: cutaneous and mucosal change; cutaneous only change; mucosal only change; cutaneous change focused on the nappy/diaper area. Mucocutaneous changes results calculated based on the first 200 subjects in the 6-12 weeks age category in each study center were enrolled, and with available data (i.e. who received a booster dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Meningitis and Encephalitis Serious Adverse Events (SAEs)</measure>
    <time_frame>At Month 0 until study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
    <description>Meningitis and encephalitis SAEs included: meningitis/encephalitis; meningitis/encephalitis viral; meningism; meningitis haemophilus; meningitis meningococcal; meningitis pneumococcal; meningitis tuberculous; encephalomyelitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Meningitis and Encephalitis SAEs</measure>
    <time_frame>From Booster up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
    <description>Meningitis and encephalitis SAEs included: meningitis/encephalitis; meningitis haemophilus; meningitis meningococcal; meningitis tuberculous; encephalomyelitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Potential Immune-mediated Disorders (pIMDs)</measure>
    <time_frame>From Month 0 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
    <description>Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within the 30-day (Days 0-29) post-primary vaccination period</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Unsolicited AEs were calculated based on the first 200 subjects enrolled in each study center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal</measure>
    <time_frame>Within the 30-day (Days 0-29) post-primary vaccination period</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the first 200 subjects enrolled in each study center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited AEs</measure>
    <time_frame>Within the 30-day (days 0-29) post-booster vaccination period</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Unsolicited AEs were calculated based on the first 200 subjects enrolled in each study center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal</measure>
    <time_frame>Within the 30-day (Days 0-29) post-primary and post-booster vaccination period in HIV-infected children</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center, who were reported with HIV infected status ((HIV status either as per general medical history taken at screening or as identified by morbidity surveillance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal in the Low-weight (LW) and Very Low-weight (VLW) Category</measure>
    <time_frame>Within the 30-day (Days 0-29) post-primary vaccination period in HIV-infected children</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center, who were reported with HIV infected status ((HIV status either as per general medical history taken at screening or as identified by morbidity surveillance). Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited AEs Related to Vaccination in the Low-weight (LW) and Very Low-weight (VLW) Category</measure>
    <time_frame>Within the 30-day (Days 0-29) post-booster vaccination period</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center. Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 0 up to Month 14</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>During the 30-day (Days 0-29) post-primary vaccination period</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adversee Events (SAEs)</measure>
    <time_frame>From Month 0 up to Month 20</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Booster (at Month 20) up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 0 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>Within the 30-day (Days 0-29) post-booster vaccination period</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 0 up to Booster (Month 20), from Month 0 up to study end and from Month 20 up to study end</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Low-weight (LW) Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 0 up to Month 20</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Low-weight (LW) Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Booster (Month 20) up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Very Low-weight (VLW) Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 0 up to Month 20</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Very Low-weight Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Booster (Month 20) up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)]</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Fatal Outcomes, by Gender</measure>
    <time_frame>From Month 0 up to study end (SE - median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
    <description>Mortality was presented as overall mortality (up to Month 20 and up to study end), mortality due to severe malaria as per secondary case definition(SCD), cerebral malaria as per secondary case definition (SCD), meningitis, fatal all-cause traumas and fatal malaria. SCD= Plasmodium falciparum malaria &gt; 5000 parasites/mcL and 1 or more markers of severe malaria (prostration, respiratory distress, Blantyre score ≤ 2, seizures 2 or more, hypoglycemia &lt; 2.2 mmol/L, acidosis BE ≤ -10.0 mmol/L,lactate ≥ 5.0 mmol/L, anemia &lt; 5.0 g/dL.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15459</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>GSK257049 [5-17M] Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK257049 [6-12W] Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin vaccines or a booster dose of Menjugate and Polio Sabin vaccines, at Month 20. All vaccines have been administered intramuscularly in the interolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VeroRab Comparator [5-17M] Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menjugate Comparator [6-12W] Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate and Polio Sabin vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Malaria Vaccine 257049</intervention_name>
    <description>administered intramuscularly into the left deltoid.</description>
    <arm_group_label>GSK257049 [5-17M] Group</arm_group_label>
    <arm_group_label>GSK257049 [6-12W] Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal C Conjugate Vaccine</intervention_name>
    <description>administered intramuscularly into the left deltoid.</description>
    <arm_group_label>GSK257049 [5-17M] Group</arm_group_label>
    <arm_group_label>GSK257049 [6-12W] Group</arm_group_label>
    <arm_group_label>Menjugate Comparator [6-12W] Group</arm_group_label>
    <arm_group_label>VeroRab Comparator [5-17M] Group</arm_group_label>
    <other_name>Menjugate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell-culture rabies vaccine</intervention_name>
    <description>administered intramuscularly into the left deltoid.</description>
    <arm_group_label>VeroRab Comparator [5-17M] Group</arm_group_label>
    <other_name>VeroRab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TritanrixHepB/Hib</intervention_name>
    <description>administered intramuscularly into the left deltoid.</description>
    <arm_group_label>GSK257049 [6-12W] Group</arm_group_label>
    <arm_group_label>Menjugate Comparator [6-12W] Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Polio Sabin Oral Polio Vaccine (GSK)</intervention_name>
    <description>administered orally.</description>
    <arm_group_label>GSK257049 [6-12W] Group</arm_group_label>
    <arm_group_label>Menjugate Comparator [6-12W] Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects must satisfy the following criteria at study entry:

          -  A male or female child of:5-17 months (inclusive) of age at time of first
             vaccination,or between 6-12 weeks of age at time of first vaccination and NOT have
             already received a dose of vaccine against diphtheria, tetanus or pertussis or
             Hemophilus influenzae type B and must be &gt; 28 days of age at screening.

          -  Signed informed consent or thumb-printed and witnessed informed consent obtained from
             the parent(s)/guardian(s) of the child.

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol.

        All subjects must satisfy the following criteria at the start of the extension phase:

          -  Subjects who were enrolled and who received at least one vaccine dose in the primary
             trial phase.

          -  Subjects who were present for Visit 35 on or before 30 September 2013.

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol (e.g. return for follow-up visits) should
             be enrolled in the study.

        Exclusion Criteria:

        The following criteria should be checked at the time of study entry. If any apply, the
        subject must not be included in the study:

          -  Acute disease at the time of enrollment.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality.

          -  Anemia associated with clinical signs or symptoms of decompensation or hemoglobin ≥
             5.0 g/dL.

          -  Major congenital defects.

          -  History of allergic reactions, significant IgE-mediated events or anaphylaxis to
             previous immunizations.

          -  Children with a past history of a neurological disorder or atypical febrile seizure.

          -  Children with malnutrition requiring hospital admission.

          -  Children currently meeting the criteria for HIV disease of Stage III or Stage IV
             severity as defined by the World Health Organization.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to a drug or vaccine that is
             not licensed for that indication with the exception of studies with the objective of
             improving the drug treatment or clinical management of severe malaria disease.

          -  Use of a drug or vaccine that is not approved for that indication other than the study
             vaccines within 30 days preceding the first dose of study vaccine, or planned use
             during the study period.

          -  Previous participation in any other malaria vaccine trial.

          -  Receipt of a vaccine within the preceding 7 days.

          -  Any other findings that the investigator feels would increase the risk of having an
             adverse outcome from participation in the trial.

          -  Any other findings that the investigator feels would result in data collected being
             incomplete or of poor quality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>17 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lambaréné</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kintampo</city>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kumasi</city>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kilifi</city>
        <zip>80108</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dar-es-Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tanga</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Gabon</country>
    <country>Ghana</country>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>Mozambique</country>
    <country>Tanzania</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kaboré B, Sombié O, Guiguemdé RT, Ouédraogo JB, Hamel MJ, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Otsyula N, Gondi S, Otieno A, Owira V, Oguk E, Odongo G, Woods JB, Ogutu B, Njuguna P, Chilengi R, Akoo P, Kerubo C, Maingi C, Lang T, Olotu A, Bejon P, Marsh K, Mwambingu G, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Dosoo D, Asante I, Adjei G, Kwara E, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Mahende C, Liheluka E, Malle L, Lemnge M, Theander TG, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Sarfo A, Agyekum A, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Tembo T, Tegha G, Tsidya M, Kilembe J, Chawinga C, Ballou WR, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Olivier A, Vekemans J, Carter T, Kaslow D, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012 Dec 13;367(24):2284-95. doi: 10.1056/NEJMoa1208394. Epub 2012 Nov 9.</citation>
    <PMID>23136909</PMID>
  </reference>
  <reference>
    <citation>RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, Mtoro A, Sykes A, Ahmed S, Urassa AM, Ali AM, Mwangoka G, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Tahita MC, Kaboré W, Ouédraogo S, Sandrine Y, Guiguemdé RT, Ouédraogo JB, Hamel MJ, Kariuki S, Odero C, Oneko M, Otieno K, Awino N, Omoto J, Williamson J, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Nekoye O, Gondi S, Otieno A, Ogutu B, Wasuna R, Owira V, Jones D, Onyango AA, Njuguna P, Chilengi R, Akoo P, Kerubo C, Gitaka J, Maingi C, Lang T, Olotu A, Tsofa B, Bejon P, Peshu N, Marsh K, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Ayamba S, Kayan K, Owusu-Ofori R, Dosoo D, Asante I, Adjei G, Adjei G, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Kilavo H, Mahende C, Liheluka E, Lemnge M, Theander T, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Agyekum A, Owusu L, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Msika A, Jumbe A, Chome N, Nyakuipa D, Chintedza J, Ballou WR, Bruls M, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Vekemans J, Carter T, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011 Nov 17;365(20):1863-75. doi: 10.1056/NEJMoa1102287. Epub 2011 Oct 18.</citation>
    <PMID>22007715</PMID>
  </reference>
  <reference>
    <citation>Leach A, Vekemans J, Lievens M, Ofori-Anyinam O, Cahill C, Owusu-Agyei S, Abdulla S, Macete E, Njuguna P, Savarese B, Loucq C, Ballou WR; Clinical Trials Partnership Committee. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J. 2011 Aug 4;10:224. doi: 10.1186/1475-2875-10-224.</citation>
    <PMID>21816029</PMID>
  </reference>
  <reference>
    <citation>Lievens M, Aponte JJ, Williamson J, Mmbando B, Mohamed A, Bejon P, Leach A. Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children. Malar J. 2011 Aug 4;10:222. doi: 10.1186/1475-2875-10-222.</citation>
    <PMID>21816030</PMID>
  </reference>
  <reference>
    <citation>Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, Lievens M, Abdulla S, Adjei S, Agbenyega T, Agnandji ST, Aide P, Anderson S, Ansong D, Aponte JJ, Asante KP, Bejon P, Birkett AJ, Bruls M, Connolly KM, D'Alessandro U, Dobaño C, Gesase S, Greenwood B, Grimsby J, Tinto H, Hamel MJ, Hoffman I, Kamthunzi P, Kariuki S, Kremsner PG, Leach A, Lell B, Lennon NJ, Lusingu J, Marsh K, Martinson F, Molel JT, Moss EL, Njuguna P, Ockenhouse CF, Ogutu BR, Otieno W, Otieno L, Otieno K, Owusu-Agyei S, Park DJ, Pellé K, Robbins D, Russ C, Ryan EM, Sacarlal J, Sogoloff B, Sorgho H, Tanner M, Theander T, Valea I, Volkman SK, Yu Q, Lapierre D, Birren BW, Gilbert PB, Wirth DF. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med. 2015 Nov 19;373(21):2025-2037. doi: 10.1056/NEJMoa1505819. Epub 2015 Oct 21.</citation>
    <PMID>26488565</PMID>
  </reference>
  <reference>
    <citation>RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014 Jul 29;11(7):e1001685. doi: 10.1371/journal.pmed.1001685. eCollection 2014 Jul.</citation>
    <PMID>25072396</PMID>
  </reference>
  <reference>
    <citation>RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015 Jul 4;386(9988):31-45. doi: 10.1016/S0140-6736(15)60721-8. Epub 2015 Apr 23. Erratum in: Lancet. 2015 Jul 4;386(9988):30.</citation>
    <PMID>25913272</PMID>
  </reference>
  <reference>
    <citation>Swysen C, Vekemans J, Bruls M, Oyakhirome S, Drakeley C, Kremsner P, Greenwood B, Ofori-Anyinam O, Okech B, Villafana T, Carter T, Savarese B, Duse A, Reijman A, Ingram C, Frean J, Ogutu B; Clinical Trials Partnership Committee. Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J. 2011 Aug 4;10:223. doi: 10.1186/1475-2875-10-223.</citation>
    <PMID>21816032</PMID>
  </reference>
  <reference>
    <citation>Vandoolaeghe P, Schuerman L. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination. Expert Rev Vaccines. 2016 Dec;15(12):1481-1493. Review.</citation>
    <PMID>27841689</PMID>
  </reference>
  <reference>
    <citation>Vekemans J, Marsh K, Greenwood B, Leach A, Kabore W, Soulanoudjingar S, Asante KP, Ansong D, Evans J, Sacarlal J, Bejon P, Kamthunzi P, Salim N, Njuguna P, Hamel MJ, Otieno W, Gesase S, Schellenberg D; Clinical Trials Partnership Committee. Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care. Malar J. 2011 Aug 4;10:221. doi: 10.1186/1475-2875-10-221.</citation>
    <PMID>21816031</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <results_first_submitted>September 21, 2017</results_first_submitted>
  <results_first_submitted_qc>September 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2019</results_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (click on the link provided below)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110021</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110021</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110021</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110021</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110021</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110021</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study included 3 phases, a primary (PRI) phase (Months 0-3) and a booster (BST) phase at Month 20, each followed by a related PRI/BST efficacy, immunogenicity and safety (EIS) follow-up (FU) phase, and an EIS extension, from Month 32 to the median of Month 48 or Month 38 time point.</recruitment_details>
      <pre_assignment_details>Screening included the following: check for inclusion/exclusion criteria, vaccination contraindications/precautions, subjects’ medical history and signing informed consent forms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK257049 [5-17M] Group</title>
          <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
        </group>
        <group group_id="P2">
          <title>GSK257049 [6-12W] Group</title>
          <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
        </group>
        <group group_id="P3">
          <title>VeroRab Comparator [5-17M] Group</title>
          <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
        </group>
        <group group_id="P4">
          <title>Menjugate Comparator [6-12W] Group</title>
          <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5948"/>
                <participants group_id="P2" count="4358"/>
                <participants group_id="P3" count="2974"/>
                <participants group_id="P4" count="2179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4102"/>
                <participants group_id="P2" count="3088"/>
                <participants group_id="P3" count="2085"/>
                <participants group_id="P4" count="1549"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1846"/>
                <participants group_id="P2" count="1270"/>
                <participants group_id="P3" count="889"/>
                <participants group_id="P4" count="630"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="587"/>
                <participants group_id="P2" count="295"/>
                <participants group_id="P3" count="272"/>
                <participants group_id="P4" count="144"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1145"/>
                <participants group_id="P2" count="830"/>
                <participants group_id="P3" count="568"/>
                <participants group_id="P4" count="425"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK257049 [5-17M] Group</title>
          <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
        </group>
        <group group_id="B2">
          <title>GSK257049 [6-12W] Group</title>
          <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
        </group>
        <group group_id="B3">
          <title>VeroRab Comparator [5-17M] Group</title>
          <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
        </group>
        <group group_id="B4">
          <title>Menjugate Comparator [6-12W] Group</title>
          <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5948"/>
            <count group_id="B2" value="4358"/>
            <count group_id="B3" value="2974"/>
            <count group_id="B4" value="2179"/>
            <count group_id="B5" value="15459"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.6" spread="3.8"/>
                    <measurement group_id="B2" value="1.2" spread="0.4"/>
                    <measurement group_id="B3" value="10.6" spread="3.7"/>
                    <measurement group_id="B4" value="1.2" spread="0.4"/>
                    <measurement group_id="B5" value="6.6" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2967"/>
                    <measurement group_id="B2" value="2124"/>
                    <measurement group_id="B3" value="1503"/>
                    <measurement group_id="B4" value="1100"/>
                    <measurement group_id="B5" value="7694"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2981"/>
                    <measurement group_id="B2" value="2234"/>
                    <measurement group_id="B3" value="1471"/>
                    <measurement group_id="B4" value="1079"/>
                    <measurement group_id="B5" value="7765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African heritage/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5948"/>
                    <measurement group_id="B2" value="4358"/>
                    <measurement group_id="B3" value="2974"/>
                    <measurement group_id="B4" value="2179"/>
                    <measurement group_id="B5" value="15459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of First or Only Clinical Episode of Plasmodium Falciparum (P. Falciparum) Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)</title>
        <description>A CPFMI-PCD was defined as an episode of malaria for which P. falciparum asexual parasitemia was greater than (&gt;) 5000 parasites per microliter (µL) accompanied by the presence of fever [axillary temperature greater than or equal to (≥) 37.5°C] at the time of presentation AND occurring in a child who is unwell and brought for treatment to a healthcare facility OR a case of malaria meeting the primary case definition of severe malaria disease. The time to first or only CPFMI-PCD is expressed in terms of rate of first or only CPFMI (RfoCPFMI), that is person-year rate in each group (n/T). Analysis for this outcome was solely performed on subjects in the 5-17 months age category.</description>
        <time_frame>From Month 2.5 to Month 14</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) population for efficacy, which included all children aged 5-17 Months who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of First or Only Clinical Episode of Plasmodium Falciparum (P. Falciparum) Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)</title>
          <description>A CPFMI-PCD was defined as an episode of malaria for which P. falciparum asexual parasitemia was greater than (&gt;) 5000 parasites per microliter (µL) accompanied by the presence of fever [axillary temperature greater than or equal to (≥) 37.5°C] at the time of presentation AND occurring in a child who is unwell and brought for treatment to a healthcare facility OR a case of malaria meeting the primary case definition of severe malaria disease. The time to first or only CPFMI-PCD is expressed in terms of rate of first or only CPFMI (RfoCPFMI), that is person-year rate in each group (n/T). Analysis for this outcome was solely performed on subjects in the 5-17 months age category.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) population for efficacy, which included all children aged 5-17 Months who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2830"/>
                <count group_id="O2" value="1466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.435"/>
                    <measurement group_id="O2" value="0.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis aimed to compare RfoCPFMI between groups over the Months 2.5-14 time period. Using RfoCFPMI, a Cox regression model was used to evaluate vaccine efficacy (VE) allowing for adjustment by factors. VE was calculated as 1 minus [Hazard Ratio (HR) in GSK257049 [5-17M] Group (HR1) divided by HR in control VeroRab Comparator [5-17M] Group (HR2)]; i. e. 1 - (HR1/HR2).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Criterion for success = lower limit (LL) of 97.5% confidence interval (CI) of VE &gt; 0.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine efficacy</param_type>
            <param_value>55.8</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>50.6</ci_lower_limit>
            <ci_upper_limit>60.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of First or Only Clinical Episode of P. Falciparum Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)</title>
        <description>A CPFMI-PCD was defined as an episode of malaria for which P. falciparum asexual parasitemia &gt; 5000 parasites/µL was accompanied by the presence of fever (axillary temperature ≥ 37.5°C) at the time of presentation AND occurring in a child who is unwell and brought for treatment to a healthcare facility OR a case of malaria meeting the primary case definition of severe malaria disease. The time to first or only CPFMI-PCD is expressed in terms of rate of first or only CPFMI (RfoCPFMI), that is, person-year rate in each group (n/T). Analysis for this outcome was solely performed on subjects in the 6-12 weeks (6-12W) age category.</description>
        <time_frame>From Month 2.5 to Month 14</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children aged 6-12 Weeks who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O2">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of First or Only Clinical Episode of P. Falciparum Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition (CPFMI-PCD)</title>
          <description>A CPFMI-PCD was defined as an episode of malaria for which P. falciparum asexual parasitemia &gt; 5000 parasites/µL was accompanied by the presence of fever (axillary temperature ≥ 37.5°C) at the time of presentation AND occurring in a child who is unwell and brought for treatment to a healthcare facility OR a case of malaria meeting the primary case definition of severe malaria disease. The time to first or only CPFMI-PCD is expressed in terms of rate of first or only CPFMI (RfoCPFMI), that is, person-year rate in each group (n/T). Analysis for this outcome was solely performed on subjects in the 6-12 weeks (6-12W) age category.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children aged 6-12 Weeks who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3995"/>
                <count group_id="O2" value="2008"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.367"/>
                    <measurement group_id="O2" value="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis aimed to compare RfoCPFMI between groups over the Months 2.5-14 time period. Using RfoCFPMI, a Cox regression model was used to evaluate vaccine efficacy (VE) allowing for adjustment by factors. VE was calculated as 1 minus [Hazard Ratio (HR) in GSK257049 [6-12W] Group (HR1) divided by HR in control Menjugate Comparator [6-12W] Group (HR2)]; i. e. 1 - (HR1/HR2).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Point estimate of efficacy was adjusted for study site as stratification factor for the analysis. Criterion for success = lower limit (LL) of 97.5% confidence interval (CI) of VE &gt; 0.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine efficacy</param_type>
            <param_value>31.315</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.556</ci_lower_limit>
            <ci_upper_limit>38.286</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of P. Falciparum Clinical Malaria Infection (CPFMI) of PCD and of Secondary Case Definitions (SCD) 1, SCD 2 and SCD 3</title>
        <description>PCD=malaria episode with P. falciparum asexual parasitemia (PFAP) &gt; 5000 parasites/µL accompanied by fever and occurring in a child unwell brought for treatment to a healthcare facility or a case of malaria meeting the PCD of severe malaria disease. SCD1=malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. SCD2=malaria episode with PFAP &gt; 500 parasites/μL and fever at time of presentation in a subject unwell brought for treatment to a healthcare facility. SCD3=malaria episode with PFAP &gt; 20.000 parasites/μL and fever at time of presentation in a subject unwell and brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine.</description>
        <time_frame>From Month 2.5 to Month 14</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of P. Falciparum Clinical Malaria Infection (CPFMI) of PCD and of Secondary Case Definitions (SCD) 1, SCD 2 and SCD 3</title>
          <description>PCD=malaria episode with P. falciparum asexual parasitemia (PFAP) &gt; 5000 parasites/µL accompanied by fever and occurring in a child unwell brought for treatment to a healthcare facility or a case of malaria meeting the PCD of severe malaria disease. SCD1=malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. SCD2=malaria episode with PFAP &gt; 500 parasites/μL and fever at time of presentation in a subject unwell brought for treatment to a healthcare facility. SCD3=malaria episode with PFAP &gt; 20.000 parasites/μL and fever at time of presentation in a subject unwell and brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2830"/>
                <count group_id="O2" value="3995"/>
                <count group_id="O3" value="1466"/>
                <count group_id="O4" value="2008"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.735"/>
                    <measurement group_id="O2" value="0.639"/>
                    <measurement group_id="O3" value="1.468"/>
                    <measurement group_id="O4" value="0.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.224"/>
                    <measurement group_id="O2" value="0.989"/>
                    <measurement group_id="O3" value="2.312"/>
                    <measurement group_id="O4" value="1.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.847"/>
                    <measurement group_id="O2" value="0.736"/>
                    <measurement group_id="O3" value="1.628"/>
                    <measurement group_id="O4" value="1.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.625"/>
                    <measurement group_id="O2" value="0.515"/>
                    <measurement group_id="O3" value="1.244"/>
                    <measurement group_id="O4" value="0.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD, Overall and by Center</title>
        <description>PCD = malaria episode with PFAP &gt; 5000 parasites/µL accompanied by fever and occurring in a child unwell brought for treatment to a healthcare facility or a case of malaria meeting the PCD of severe malaria disease (see below endpoints on severe malaria for details). Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are by center and across centers, and are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine.</description>
        <time_frame>From Month 2.5 to Month 20</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3. Data was not collected for the participants in the 5-17M groups for the Manhica site.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD, Overall and by Center</title>
          <description>PCD = malaria episode with PFAP &gt; 5000 parasites/µL accompanied by fever and occurring in a child unwell brought for treatment to a healthcare facility or a case of malaria meeting the PCD of severe malaria disease (see below endpoints on severe malaria for details). Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are by center and across centers, and are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3. Data was not collected for the participants in the 5-17M groups for the Manhica site.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4557"/>
                <count group_id="O2" value="3996"/>
                <count group_id="O3" value="2328"/>
                <count group_id="O4" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCD – Agogo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="418"/>
                    <count group_id="O3" value="192"/>
                    <count group_id="O4" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56"/>
                    <measurement group_id="O2" value="0.64"/>
                    <measurement group_id="O3" value="1.16"/>
                    <measurement group_id="O4" value="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Bagamoyo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="462"/>
                    <count group_id="O2" value="502"/>
                    <count group_id="O3" value="235"/>
                    <count group_id="O4" value="244"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.08"/>
                    <measurement group_id="O3" value="0.28"/>
                    <measurement group_id="O4" value="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Kilifi</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="186"/>
                    <count group_id="O3" value="171"/>
                    <count group_id="O4" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.04"/>
                    <measurement group_id="O3" value="0.04"/>
                    <measurement group_id="O4" value="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Kintampo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="602"/>
                    <count group_id="O2" value="199"/>
                    <count group_id="O3" value="296"/>
                    <count group_id="O4" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01"/>
                    <measurement group_id="O2" value="1.53"/>
                    <measurement group_id="O3" value="1.85"/>
                    <measurement group_id="O4" value="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Kombewa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="609"/>
                    <count group_id="O2" value="387"/>
                    <count group_id="O3" value="311"/>
                    <count group_id="O4" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21"/>
                    <measurement group_id="O2" value="0.94"/>
                    <measurement group_id="O3" value="1.87"/>
                    <measurement group_id="O4" value="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Korogwe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="568"/>
                    <count group_id="O2" value="382"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.11"/>
                    <measurement group_id="O4" value="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Lambarene</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="380"/>
                    <count group_id="O2" value="147"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11"/>
                    <measurement group_id="O2" value="0.11"/>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Lilongwe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="359"/>
                    <count group_id="O2" value="500"/>
                    <count group_id="O3" value="183"/>
                    <count group_id="O4" value="258"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.32"/>
                    <measurement group_id="O4" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Manhica</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="381"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.1"/>
                    <measurement group_id="O4" value="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Nanoro</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="389"/>
                    <count group_id="O2" value="441"/>
                    <count group_id="O3" value="198"/>
                    <count group_id="O4" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42"/>
                    <measurement group_id="O2" value="1.93"/>
                    <measurement group_id="O3" value="2.4"/>
                    <measurement group_id="O4" value="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Siaya</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="481"/>
                    <count group_id="O2" value="453"/>
                    <count group_id="O3" value="253"/>
                    <count group_id="O4" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01"/>
                    <measurement group_id="O2" value="2.03"/>
                    <measurement group_id="O3" value="3.31"/>
                    <measurement group_id="O4" value="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Across</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4557"/>
                    <count group_id="O2" value="3996"/>
                    <count group_id="O3" value="2328"/>
                    <count group_id="O4" value="2007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69"/>
                    <measurement group_id="O2" value="0.71"/>
                    <measurement group_id="O3" value="1.17"/>
                    <measurement group_id="O4" value="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of SCD1, SCD2 and SCD3 (Overall)</title>
        <description>SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. SCD2 = malaria episode with PFAP &gt; 500 parasites/μL and fever at time of presentation in a subject unwell brought for treatment to a healthcare facility. SCD3 = malaria episode with PFAP &gt; 20.000 parasites/μL and fever at time of presentation in a subject unwell and brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are across centers, and are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine.</description>
        <time_frame>From Month 2.5 to Month 20</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of SCD1, SCD2 and SCD3 (Overall)</title>
          <description>SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. SCD2 = malaria episode with PFAP &gt; 500 parasites/μL and fever at time of presentation in a subject unwell brought for treatment to a healthcare facility. SCD3 = malaria episode with PFAP &gt; 20.000 parasites/μL and fever at time of presentation in a subject unwell and brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are across centers, and are uncorrected for double enrollment of 1 subject receiving GSK257049 vaccine.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4557"/>
                <count group_id="O2" value="3996"/>
                <count group_id="O3" value="2328"/>
                <count group_id="O4" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09"/>
                    <measurement group_id="O2" value="1.09"/>
                    <measurement group_id="O3" value="1.78"/>
                    <measurement group_id="O4" value="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78"/>
                    <measurement group_id="O2" value="0.81"/>
                    <measurement group_id="O3" value="1.3"/>
                    <measurement group_id="O4" value="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59"/>
                    <measurement group_id="O2" value="0.58"/>
                    <measurement group_id="O3" value="1.01"/>
                    <measurement group_id="O4" value="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Centers and Across Centers</title>
        <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented by center and across centers.</description>
        <time_frame>From Month 2.5 up to study End (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3. Data was not collected for the participants in the 5-17M groups for the Manhica site.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Centers and Across Centers</title>
          <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented by center and across centers.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3. Data was not collected for the participants in the 5-17M groups for the Manhica site.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2276"/>
                <count group_id="O2" value="2306"/>
                <count group_id="O3" value="2336"/>
                <count group_id="O4" value="1985"/>
                <count group_id="O5" value="2005"/>
                <count group_id="O6" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCD – Kilifi</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="163"/>
                    <count group_id="O2" value="172"/>
                    <count group_id="O3" value="172"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="95"/>
                    <count group_id="O6" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.08"/>
                    <measurement group_id="O4" value="0.06"/>
                    <measurement group_id="O5" value="0.04"/>
                    <measurement group_id="O6" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Korogwe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="282"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="191"/>
                    <count group_id="O5" value="191"/>
                    <count group_id="O6" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                    <measurement group_id="O2" value="0.05"/>
                    <measurement group_id="O3" value="0.1"/>
                    <measurement group_id="O4" value="0.05"/>
                    <measurement group_id="O5" value="0.07"/>
                    <measurement group_id="O6" value="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Lambarene</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="196"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="75"/>
                    <count group_id="O6" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15"/>
                    <measurement group_id="O2" value="0.15"/>
                    <measurement group_id="O3" value="0.23"/>
                    <measurement group_id="O4" value="0.1"/>
                    <measurement group_id="O5" value="0.18"/>
                    <measurement group_id="O6" value="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Bagamoyo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="236"/>
                    <count group_id="O4" value="252"/>
                    <count group_id="O5" value="249"/>
                    <count group_id="O6" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16"/>
                    <measurement group_id="O2" value="0.21"/>
                    <measurement group_id="O3" value="0.27"/>
                    <measurement group_id="O4" value="0.08"/>
                    <measurement group_id="O5" value="0.11"/>
                    <measurement group_id="O6" value="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Lilongwe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="247"/>
                    <count group_id="O5" value="250"/>
                    <count group_id="O6" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.23"/>
                    <measurement group_id="O4" value="0.25"/>
                    <measurement group_id="O5" value="0.29"/>
                    <measurement group_id="O6" value="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Agogo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="191"/>
                    <count group_id="O4" value="209"/>
                    <count group_id="O5" value="209"/>
                    <count group_id="O6" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59"/>
                    <measurement group_id="O2" value="0.73"/>
                    <measurement group_id="O3" value="1.01"/>
                    <measurement group_id="O4" value="0.59"/>
                    <measurement group_id="O5" value="0.77"/>
                    <measurement group_id="O6" value="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Kombewa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="315"/>
                    <count group_id="O2" value="301"/>
                    <count group_id="O3" value="312"/>
                    <count group_id="O4" value="195"/>
                    <count group_id="O5" value="193"/>
                    <count group_id="O6" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26"/>
                    <measurement group_id="O2" value="1.37"/>
                    <measurement group_id="O3" value="1.64"/>
                    <measurement group_id="O4" value="1.37"/>
                    <measurement group_id="O5" value="1.37"/>
                    <measurement group_id="O6" value="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Kintampo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="310"/>
                    <count group_id="O3" value="301"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="101"/>
                    <count group_id="O6" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11"/>
                    <measurement group_id="O2" value="1.31"/>
                    <measurement group_id="O3" value="1.71"/>
                    <measurement group_id="O4" value="1.65"/>
                    <measurement group_id="O5" value="1.71"/>
                    <measurement group_id="O6" value="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Manhica</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="193"/>
                    <count group_id="O5" value="187"/>
                    <count group_id="O6" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.18"/>
                    <measurement group_id="O5" value="0.14"/>
                    <measurement group_id="O6" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Nanoro</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="198"/>
                    <count group_id="O4" value="217"/>
                    <count group_id="O5" value="224"/>
                    <count group_id="O6" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95"/>
                    <measurement group_id="O2" value="2.18"/>
                    <measurement group_id="O3" value="2.69"/>
                    <measurement group_id="O4" value="2.59"/>
                    <measurement group_id="O5" value="2.79"/>
                    <measurement group_id="O6" value="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Siaya</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="252"/>
                    <count group_id="O4" value="221"/>
                    <count group_id="O5" value="231"/>
                    <count group_id="O6" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09"/>
                    <measurement group_id="O2" value="2.55"/>
                    <measurement group_id="O3" value="3.15"/>
                    <measurement group_id="O4" value="2.43"/>
                    <measurement group_id="O5" value="2.67"/>
                    <measurement group_id="O6" value="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Across</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2276"/>
                    <count group_id="O2" value="2306"/>
                    <count group_id="O3" value="2336"/>
                    <count group_id="O4" value="1985"/>
                    <count group_id="O5" value="2005"/>
                    <count group_id="O6" value="2007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="1.14"/>
                    <measurement group_id="O4" value="0.86"/>
                    <measurement group_id="O5" value="0.95"/>
                    <measurement group_id="O6" value="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Secondary Case Definition 1 (SCD1), Across Centers</title>
        <description>CPFMI of SCD1 = malaria episode with PFAP &gt;0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented across centers.</description>
        <time_frame>From Month 2.5 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Secondary Case Definition 1 (SCD1), Across Centers</title>
          <description>CPFMI of SCD1 = malaria episode with PFAP &gt;0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented across centers.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2276"/>
                <count group_id="O2" value="2306"/>
                <count group_id="O3" value="2336"/>
                <count group_id="O4" value="1985"/>
                <count group_id="O5" value="2005"/>
                <count group_id="O6" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26"/>
                    <measurement group_id="O2" value="1.41"/>
                    <measurement group_id="O3" value="1.81"/>
                    <measurement group_id="O4" value="1.29"/>
                    <measurement group_id="O5" value="1.43"/>
                    <measurement group_id="O6" value="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD) and Secondary Case Definition 1 (SCD1), Across Centers</title>
        <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. CPFMI of SCD1 = malaria episode with PFAP &gt;0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented across centers.</description>
        <time_frame>From Booster at Month 20 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD) and Secondary Case Definition 1 (SCD1), Across Centers</title>
          <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. CPFMI of SCD1 = malaria episode with PFAP &gt;0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented across centers.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2017"/>
                <count group_id="O2" value="2057"/>
                <count group_id="O3" value="2050"/>
                <count group_id="O4" value="1743"/>
                <count group_id="O5" value="1788"/>
                <count group_id="O6" value="1762"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87"/>
                    <measurement group_id="O2" value="1.03"/>
                    <measurement group_id="O3" value="1.1"/>
                    <measurement group_id="O4" value="1.01"/>
                    <measurement group_id="O5" value="1.21"/>
                    <measurement group_id="O6" value="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39"/>
                    <measurement group_id="O2" value="1.65"/>
                    <measurement group_id="O3" value="1.82"/>
                    <measurement group_id="O4" value="1.48"/>
                    <measurement group_id="O5" value="1.79"/>
                    <measurement group_id="O6" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD and SCD1, Across Centers</title>
        <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. CPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented across centers.</description>
        <time_frame>From Month 33 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD and SCD1, Across Centers</title>
          <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. CPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented across centers.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1784"/>
                <count group_id="O2" value="1838"/>
                <count group_id="O3" value="1864"/>
                <count group_id="O4" value="1516"/>
                <count group_id="O5" value="1548"/>
                <count group_id="O6" value="1546"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1784"/>
                    <count group_id="O2" value="1838"/>
                    <count group_id="O3" value="1864"/>
                    <count group_id="O4" value="1516"/>
                    <count group_id="O5" value="1548"/>
                    <count group_id="O6" value="1546"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="1.1"/>
                    <measurement group_id="O4" value="1.18"/>
                    <measurement group_id="O5" value="1.31"/>
                    <measurement group_id="O6" value="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1784"/>
                    <count group_id="O2" value="1838"/>
                    <count group_id="O3" value="1864"/>
                    <count group_id="O4" value="1516"/>
                    <count group_id="O5" value="1547"/>
                    <count group_id="O6" value="1546"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61"/>
                    <measurement group_id="O2" value="1.79"/>
                    <measurement group_id="O3" value="1.88"/>
                    <measurement group_id="O4" value="1.73"/>
                    <measurement group_id="O5" value="1.92"/>
                    <measurement group_id="O6" value="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD, by Center and Across Centers</title>
        <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented by center and across centers.</description>
        <time_frame>From Month 2.5 to Month 32</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3. Data was not collected for the participants in the 5-17M groups for the Manhica site.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of PCD, by Center and Across Centers</title>
          <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all CPFMI episodes is expressed as person-year rate in each group (n/T). Results are presented by center and across centers.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3. Data was not collected for the participants in the 5-17M groups for the Manhica site.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2276"/>
                <count group_id="O2" value="2306"/>
                <count group_id="O3" value="2336"/>
                <count group_id="O4" value="1985"/>
                <count group_id="O5" value="2005"/>
                <count group_id="O6" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCD – Kilifi</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="163"/>
                    <count group_id="O2" value="172"/>
                    <count group_id="O3" value="172"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="95"/>
                    <count group_id="O6" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.04"/>
                    <measurement group_id="O3" value="0.09"/>
                    <measurement group_id="O4" value="0.06"/>
                    <measurement group_id="O5" value="0.04"/>
                    <measurement group_id="O6" value="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Korogwe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                    <count group_id="O2" value="282"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="191"/>
                    <count group_id="O5" value="191"/>
                    <count group_id="O6" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.08"/>
                    <measurement group_id="O4" value="0.02"/>
                    <measurement group_id="O5" value="0.06"/>
                    <measurement group_id="O6" value="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Lambarene</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="196"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="75"/>
                    <count group_id="O6" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14"/>
                    <measurement group_id="O2" value="0.14"/>
                    <measurement group_id="O3" value="0.21"/>
                    <measurement group_id="O4" value="0.1"/>
                    <measurement group_id="O5" value="0.18"/>
                    <measurement group_id="O6" value="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Bagamoyo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="236"/>
                    <count group_id="O4" value="252"/>
                    <count group_id="O5" value="249"/>
                    <count group_id="O6" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13"/>
                    <measurement group_id="O2" value="0.19"/>
                    <measurement group_id="O3" value="0.31"/>
                    <measurement group_id="O4" value="0.08"/>
                    <measurement group_id="O5" value="0.11"/>
                    <measurement group_id="O6" value="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Lilongwe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="185"/>
                    <count group_id="O4" value="247"/>
                    <count group_id="O5" value="250"/>
                    <count group_id="O6" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11"/>
                    <measurement group_id="O2" value="0.22"/>
                    <measurement group_id="O3" value="0.29"/>
                    <measurement group_id="O4" value="0.27"/>
                    <measurement group_id="O5" value="0.32"/>
                    <measurement group_id="O6" value="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Agogo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="183"/>
                    <count group_id="O3" value="191"/>
                    <count group_id="O4" value="209"/>
                    <count group_id="O5" value="209"/>
                    <count group_id="O6" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59"/>
                    <measurement group_id="O2" value="0.75"/>
                    <measurement group_id="O3" value="1.15"/>
                    <measurement group_id="O4" value="0.56"/>
                    <measurement group_id="O5" value="0.72"/>
                    <measurement group_id="O6" value="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Kombewa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="315"/>
                    <count group_id="O2" value="301"/>
                    <count group_id="O3" value="312"/>
                    <count group_id="O4" value="195"/>
                    <count group_id="O5" value="193"/>
                    <count group_id="O6" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12"/>
                    <measurement group_id="O2" value="1.29"/>
                    <measurement group_id="O3" value="1.67"/>
                    <measurement group_id="O4" value="1.28"/>
                    <measurement group_id="O5" value="1.25"/>
                    <measurement group_id="O6" value="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Kintampo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="310"/>
                    <count group_id="O3" value="301"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="101"/>
                    <count group_id="O6" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08"/>
                    <measurement group_id="O2" value="1.17"/>
                    <measurement group_id="O3" value="1.87"/>
                    <measurement group_id="O4" value="1.52"/>
                    <measurement group_id="O5" value="1.6"/>
                    <measurement group_id="O6" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Manhica</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="193"/>
                    <count group_id="O5" value="187"/>
                    <count group_id="O6" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.15"/>
                    <measurement group_id="O5" value="0.12"/>
                    <measurement group_id="O6" value="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Nanoro</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="198"/>
                    <count group_id="O4" value="217"/>
                    <count group_id="O5" value="224"/>
                    <count group_id="O6" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42"/>
                    <measurement group_id="O2" value="1.67"/>
                    <measurement group_id="O3" value="2.45"/>
                    <measurement group_id="O4" value="2.27"/>
                    <measurement group_id="O5" value="2.53"/>
                    <measurement group_id="O6" value="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Siaya</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="252"/>
                    <count group_id="O4" value="221"/>
                    <count group_id="O5" value="231"/>
                    <count group_id="O6" value="229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91"/>
                    <measurement group_id="O2" value="2.46"/>
                    <measurement group_id="O3" value="3.25"/>
                    <measurement group_id="O4" value="2.41"/>
                    <measurement group_id="O5" value="2.54"/>
                    <measurement group_id="O6" value="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD – Across</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2276"/>
                    <count group_id="O2" value="2306"/>
                    <count group_id="O3" value="2336"/>
                    <count group_id="O4" value="1985"/>
                    <count group_id="O5" value="2005"/>
                    <count group_id="O6" value="2007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68"/>
                    <measurement group_id="O2" value="0.81"/>
                    <measurement group_id="O3" value="1.15"/>
                    <measurement group_id="O4" value="0.8"/>
                    <measurement group_id="O5" value="0.88"/>
                    <measurement group_id="O6" value="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Secondary Case Definition 1 (SCD1)</title>
        <description>CPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T).</description>
        <time_frame>From Month 2.5 to Month 32</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Secondary Case Definition 1 (SCD1)</title>
          <description>CPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T).</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2276"/>
                <count group_id="O2" value="2306"/>
                <count group_id="O3" value="2336"/>
                <count group_id="O4" value="1985"/>
                <count group_id="O5" value="2005"/>
                <count group_id="O6" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.24"/>
                    <measurement group_id="O3" value="1.78"/>
                    <measurement group_id="O4" value="1.19"/>
                    <measurement group_id="O5" value="1.33"/>
                    <measurement group_id="O6" value="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD) and Secondary Case Definition 1 (SCD1)</title>
        <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. CPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T).</description>
        <time_frame>From Booster at Month 20 up to Month 32</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD) and Secondary Case Definition 1 (SCD1)</title>
          <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. CPFMI of SCD1 = malaria episode with PFAP &gt; 0 and fever at time of presentation or history of fever within 24h of presentation in a subject unwell brought for treatment to a healthcare facility. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T).</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2017"/>
                <count group_id="O2" value="2057"/>
                <count group_id="O3" value="2050"/>
                <count group_id="O4" value="1743"/>
                <count group_id="O5" value="1788"/>
                <count group_id="O6" value="1762"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72"/>
                    <measurement group_id="O2" value="0.96"/>
                    <measurement group_id="O3" value="1.1"/>
                    <measurement group_id="O4" value="0.91"/>
                    <measurement group_id="O5" value="1.15"/>
                    <measurement group_id="O6" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14"/>
                    <measurement group_id="O2" value="1.48"/>
                    <measurement group_id="O3" value="1.74"/>
                    <measurement group_id="O4" value="1.35"/>
                    <measurement group_id="O5" value="1.72"/>
                    <measurement group_id="O6" value="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Severe PFMI (SPFMI) of PCD, SCD1, SCD2 and SCD3, Across Centers</title>
        <description>SPFMI of PCD = PFMI &gt; 5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI &gt;5000 parasites/μL and with one or more severity marker. SPFMI of SCD2 = PFMI &gt;0 with one or more severity marker and without co-morbidity diagnosis. SPFMI of SCD3 = PFMI &gt;5000 parasites/μL, with one or more severity marker, and without co-morbidity or HIV. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia &lt; 2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l &lt; 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72 h of admission; gastroenteritis with dehydration. Analysis was performed in a pooled manner across age categories. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine.</description>
        <time_frame>From Month 2.5 up to the time when 250 subjects were diagnosed with severe malaria of PCD, SCD1, SCD2 and SCD3 (up to the Month 14 time point for each age category or date of booster dose, whichever occurred first)</time_frame>
        <population>The analysis was performed, across age categories for which groups were pooled from the ATP population for efficacy. This included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 Group</title>
            <description>For the purpose of the analysis, GSK257049 [5-17M] and GSK257049 [6-12W] groups have been pooled into a single group.</description>
          </group>
          <group group_id="O2">
            <title>Comparator Group</title>
            <description>For the purpose of the analysis, VeroRab Comparator [5-17M] and Menjugate Comparator [6-12W] groups have been pooled into a single group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Severe PFMI (SPFMI) of PCD, SCD1, SCD2 and SCD3, Across Centers</title>
          <description>SPFMI of PCD = PFMI &gt; 5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI &gt;5000 parasites/μL and with one or more severity marker. SPFMI of SCD2 = PFMI &gt;0 with one or more severity marker and without co-morbidity diagnosis. SPFMI of SCD3 = PFMI &gt;5000 parasites/μL, with one or more severity marker, and without co-morbidity or HIV. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia &lt; 2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l &lt; 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72 h of admission; gastroenteritis with dehydration. Analysis was performed in a pooled manner across age categories. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine.</description>
          <population>The analysis was performed, across age categories for which groups were pooled from the ATP population for efficacy. This included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8597"/>
                <count group_id="O2" value="4364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019"/>
                    <measurement group_id="O2" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023"/>
                    <measurement group_id="O2" value="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023"/>
                    <measurement group_id="O2" value="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019"/>
                    <measurement group_id="O2" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1</title>
        <description>SPFMI of PCD = PFMI&gt;5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72h of admission; gastroenteritis with dehydration. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category.</description>
        <time_frame>From Month 2.5 to Month 14</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1</title>
          <description>SPFMI of PCD = PFMI&gt;5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72h of admission; gastroenteritis with dehydration. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2830"/>
                <count group_id="O2" value="3995"/>
                <count group_id="O3" value="1466"/>
                <count group_id="O4" value="2008"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SPFMI PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="3.8"/>
                    <measurement group_id="O4" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPFMI SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1</title>
        <description>SPFMI of PCD = PFMI&gt;5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72h of admission; gastroenteritis with dehydration. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category.</description>
        <time_frame>From Month 2.5 to Month 20 at Booster</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1</title>
          <description>SPFMI of PCD = PFMI&gt;5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72h of admission; gastroenteritis with dehydration. SPFMI of SCD1 = PFMI&gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4557"/>
                <count group_id="O2" value="3996"/>
                <count group_id="O3" value="2328"/>
                <count group_id="O4" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SPFMI PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.04"/>
                    <measurement group_id="O4" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPFMI SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.05"/>
                    <measurement group_id="O4" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1</title>
        <description>SPFMI of PCD = PFMI &gt;5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI &gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72 h of admission; gastroenteritis with dehydration. SPFMI of SCD1 = PFMI &gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL.</description>
        <time_frame>From Month 2.5, from Month 20(booster), from Month 33 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17M age category and of 38 months post-Dose 1 for 6-12W age category) and from Month 2.5 to Month 32 and from Month 20 to Month 32</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Severe PFMI (SPFMI) of PCD and SCD1</title>
          <description>SPFMI of PCD = PFMI &gt;5000 parasites/μL, at least one severity marker and no co-morbidity diagnosis. SPFMI of SCD1 = PFMI &gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL. Comorbidities = radiographically proven pneumonia; meningitis; positive blood culture on a blood culture taken within 72 h of admission; gastroenteritis with dehydration. SPFMI of SCD1 = PFMI &gt;5000 parasites/μL and with one or more severity marker. Severity markers = prostration; respiratory distress; Blantyre score ≤ 2; ≥ 2 seizures in 24 h prior to admission, emergency room and hospitalisation; hypoglycaemia&lt;2.2 mmol/L; acidosis BE ≤ -10.0 mmol/L,l ≥ 5.0 mmol/L; anaemia&lt;5.0 g/dL.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2276"/>
                <count group_id="O2" value="2306"/>
                <count group_id="O3" value="2336"/>
                <count group_id="O4" value="1985"/>
                <count group_id="O5" value="2005"/>
                <count group_id="O6" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCD, M2.5 to SE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2276"/>
                    <count group_id="O2" value="2306"/>
                    <count group_id="O3" value="2336"/>
                    <count group_id="O4" value="1985"/>
                    <count group_id="O5" value="2005"/>
                    <count group_id="O6" value="2007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                    <measurement group_id="O2" value="0.06"/>
                    <measurement group_id="O3" value="0.06"/>
                    <measurement group_id="O4" value="0.04"/>
                    <measurement group_id="O5" value="0.04"/>
                    <measurement group_id="O6" value="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD, M20 to SE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2017"/>
                    <count group_id="O2" value="2057"/>
                    <count group_id="O3" value="2051"/>
                    <count group_id="O4" value="1743"/>
                    <count group_id="O5" value="1788"/>
                    <count group_id="O6" value="1762"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.04"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.02"/>
                    <measurement group_id="O5" value="0.03"/>
                    <measurement group_id="O6" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD, M33 to SE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1784"/>
                    <count group_id="O2" value="1838"/>
                    <count group_id="O3" value="1864"/>
                    <count group_id="O4" value="1516"/>
                    <count group_id="O5" value="1548"/>
                    <count group_id="O6" value="1546"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.01"/>
                    <measurement group_id="O5" value="0.01"/>
                    <measurement group_id="O6" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD, M2.5 to M32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2276"/>
                    <count group_id="O2" value="2306"/>
                    <count group_id="O3" value="2336"/>
                    <count group_id="O4" value="1985"/>
                    <count group_id="O5" value="2005"/>
                    <count group_id="O6" value="2007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.05"/>
                    <measurement group_id="O3" value="0.05"/>
                    <measurement group_id="O4" value="0.04"/>
                    <measurement group_id="O5" value="0.04"/>
                    <measurement group_id="O6" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD, M20 to M32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2017"/>
                    <count group_id="O2" value="2057"/>
                    <count group_id="O3" value="2051"/>
                    <count group_id="O4" value="1743"/>
                    <count group_id="O5" value="1788"/>
                    <count group_id="O6" value="1762"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.01"/>
                    <measurement group_id="O5" value="0.02"/>
                    <measurement group_id="O6" value="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD1, M2.5 to SE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2276"/>
                    <count group_id="O2" value="2306"/>
                    <count group_id="O3" value="2336"/>
                    <count group_id="O4" value="1985"/>
                    <count group_id="O5" value="2005"/>
                    <count group_id="O6" value="2007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05"/>
                    <measurement group_id="O2" value="0.07"/>
                    <measurement group_id="O3" value="0.07"/>
                    <measurement group_id="O4" value="0.04"/>
                    <measurement group_id="O5" value="0.05"/>
                    <measurement group_id="O6" value="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD1, M20 to SE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2017"/>
                    <count group_id="O2" value="2057"/>
                    <count group_id="O3" value="2051"/>
                    <count group_id="O4" value="1743"/>
                    <count group_id="O5" value="1788"/>
                    <count group_id="O6" value="1762"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.04"/>
                    <measurement group_id="O3" value="0.03"/>
                    <measurement group_id="O4" value="0.02"/>
                    <measurement group_id="O5" value="0.03"/>
                    <measurement group_id="O6" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD1, M33 to SE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1784"/>
                    <count group_id="O2" value="1838"/>
                    <count group_id="O3" value="1864"/>
                    <count group_id="O4" value="1516"/>
                    <count group_id="O5" value="1548"/>
                    <count group_id="O6" value="1546"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.01"/>
                    <measurement group_id="O5" value="0.01"/>
                    <measurement group_id="O6" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD1, M2.5 to M32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2276"/>
                    <count group_id="O2" value="2306"/>
                    <count group_id="O3" value="2336"/>
                    <count group_id="O4" value="1985"/>
                    <count group_id="O5" value="2005"/>
                    <count group_id="O6" value="2007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                    <measurement group_id="O2" value="0.06"/>
                    <measurement group_id="O3" value="0.06"/>
                    <measurement group_id="O4" value="0.04"/>
                    <measurement group_id="O5" value="0.04"/>
                    <measurement group_id="O6" value="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCD1, M20 to M32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2017"/>
                    <count group_id="O2" value="2057"/>
                    <count group_id="O3" value="2051"/>
                    <count group_id="O4" value="1743"/>
                    <count group_id="O5" value="1788"/>
                    <count group_id="O6" value="1762"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.01"/>
                    <measurement group_id="O5" value="0.02"/>
                    <measurement group_id="O6" value="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Incident Severe Anaemia (ISA) and Malaria Hospitalization (MH) for Case Definitions (CD) Considered</title>
        <description>CD considered were CD1 for ISA and CD1 and CD2 for MH. ISA of CD1 was defined as a documented hemoglobin &lt; 5.0 g/dL identified at clinical presentation to morbidity surveillance system in association with a P. falciparum parasitemia &gt; 5000 parasites/μL. MH of CD1 was defined as a medical hospitalization with confirmed P. falciparum &gt; 5000 parasites/μL. MH of CD2 was defined as a hospitalization which, in the judgment of the principal investigator, P. falciparum infection was the sole or a major contributing factor to the presentation. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine.</description>
        <time_frame>From Month 2.5 to Month 20</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Incident Severe Anaemia (ISA) and Malaria Hospitalization (MH) for Case Definitions (CD) Considered</title>
          <description>CD considered were CD1 for ISA and CD1 and CD2 for MH. ISA of CD1 was defined as a documented hemoglobin &lt; 5.0 g/dL identified at clinical presentation to morbidity surveillance system in association with a P. falciparum parasitemia &gt; 5000 parasites/μL. MH of CD1 was defined as a medical hospitalization with confirmed P. falciparum &gt; 5000 parasites/μL. MH of CD2 was defined as a hospitalization which, in the judgment of the principal investigator, P. falciparum infection was the sole or a major contributing factor to the presentation. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4557"/>
                <count group_id="O2" value="3996"/>
                <count group_id="O3" value="2328"/>
                <count group_id="O4" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ISA CD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MH CD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05"/>
                    <measurement group_id="O2" value="0.04"/>
                    <measurement group_id="O3" value="0.09"/>
                    <measurement group_id="O4" value="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MH CD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06"/>
                    <measurement group_id="O2" value="0.05"/>
                    <measurement group_id="O3" value="0.1"/>
                    <measurement group_id="O4" value="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Incident Severe Anaemia (ISA), Malaria Hospitalization (MH) and Fatal Malaria (FM) for Case Definitions (CD) Considered</title>
        <description>ISA CD considered were CD1, CD2 and CD3 (definitions mentioned in the previous outcome measure). MH CD considered were CD1 and CD2 (definitions mentioned in the previous outcome measure).FM CD considered were primary CD (PCD) and sedondary CDs 1 and 4 (SCD1 and SCD4). FM of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease with a fatal outcome. FM of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease with a fatal outcome. FM of SCD4 was defined as a fatal case associated with International Classification Disease (ICD10) codes B50, B53 and/or B54. Code B50 corresponds to P. falciparum malaria including mixed infections of P. falciparum with any other Plasmodium species; Code B53 corresponds to other parasitologically confirmed malaria; Code B54 corresponds to unspecified malaria including clinically diagnosed malaria without parasitological confirmation.</description>
        <time_frame>From Month 2.5 to up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Incident Severe Anaemia (ISA), Malaria Hospitalization (MH) and Fatal Malaria (FM) for Case Definitions (CD) Considered</title>
          <description>ISA CD considered were CD1, CD2 and CD3 (definitions mentioned in the previous outcome measure). MH CD considered were CD1 and CD2 (definitions mentioned in the previous outcome measure).FM CD considered were primary CD (PCD) and sedondary CDs 1 and 4 (SCD1 and SCD4). FM of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease with a fatal outcome. FM of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease with a fatal outcome. FM of SCD4 was defined as a fatal case associated with International Classification Disease (ICD10) codes B50, B53 and/or B54. Code B50 corresponds to P. falciparum malaria including mixed infections of P. falciparum with any other Plasmodium species; Code B53 corresponds to other parasitologically confirmed malaria; Code B54 corresponds to unspecified malaria including clinically diagnosed malaria without parasitological confirmation.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2276"/>
                <count group_id="O2" value="2306"/>
                <count group_id="O3" value="2336"/>
                <count group_id="O4" value="1985"/>
                <count group_id="O5" value="2005"/>
                <count group_id="O6" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ISA CD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.01"/>
                    <measurement group_id="O5" value="0.01"/>
                    <measurement group_id="O6" value="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISA CD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.01"/>
                    <measurement group_id="O5" value="0.02"/>
                    <measurement group_id="O6" value="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISA CD3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.02"/>
                    <measurement group_id="O5" value="0.03"/>
                    <measurement group_id="O6" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MH CD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07"/>
                    <measurement group_id="O2" value="0.1"/>
                    <measurement group_id="O3" value="0.12"/>
                    <measurement group_id="O4" value="0.06"/>
                    <measurement group_id="O5" value="0.07"/>
                    <measurement group_id="O6" value="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MH CD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09"/>
                    <measurement group_id="O2" value="0.11"/>
                    <measurement group_id="O3" value="0.13"/>
                    <measurement group_id="O4" value="0.08"/>
                    <measurement group_id="O5" value="0.09"/>
                    <measurement group_id="O6" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FM PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FM SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FM SCD4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0.01"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Incident Severe Anaemia (ISA), Malaria Hospitalization (MH) and Fatal Malaria (FM) for Case Definitions (CD) Considered</title>
        <description>ISA CD considered were CD1, CD2 and CD3 (definitions mentioned in the previous outcome measure). MH CD considered were CD1 and CD2 (definitions mentioned in the previous outcome measure).FM CD considered were primary CD (PCD) and sedondary CDs 1 and 4 (SCD1 and SCD4). FM of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease with a fatal outcome. FM of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease with a fatal outcome. FM of SCD4 was defined as a fatal case associated with International Classification Disease (ICD10) codes B50, B53 and/or B54. Code B50 corresponds to P. falciparum malaria including mixed infections of P. falciparum with any other Plasmodium species; Code B53 corresponds to other parasitologically confirmed malaria; Code B54 corresponds to unspecified malaria including clinically diagnosed malaria without parasitological confirmation.</description>
        <time_frame>From Month 2.5 to Month 32</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Incident Severe Anaemia (ISA), Malaria Hospitalization (MH) and Fatal Malaria (FM) for Case Definitions (CD) Considered</title>
          <description>ISA CD considered were CD1, CD2 and CD3 (definitions mentioned in the previous outcome measure). MH CD considered were CD1 and CD2 (definitions mentioned in the previous outcome measure).FM CD considered were primary CD (PCD) and sedondary CDs 1 and 4 (SCD1 and SCD4). FM of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease with a fatal outcome. FM of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease with a fatal outcome. FM of SCD4 was defined as a fatal case associated with International Classification Disease (ICD10) codes B50, B53 and/or B54. Code B50 corresponds to P. falciparum malaria including mixed infections of P. falciparum with any other Plasmodium species; Code B53 corresponds to other parasitologically confirmed malaria; Code B54 corresponds to unspecified malaria including clinically diagnosed malaria without parasitological confirmation.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2276"/>
                <count group_id="O2" value="2306"/>
                <count group_id="O3" value="2336"/>
                <count group_id="O4" value="1985"/>
                <count group_id="O5" value="2005"/>
                <count group_id="O6" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ISA CD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.1"/>
                    <measurement group_id="O5" value="0.01"/>
                    <measurement group_id="O6" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISA CD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.01"/>
                    <measurement group_id="O5" value="0.01"/>
                    <measurement group_id="O6" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISA CD3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.02"/>
                    <measurement group_id="O5" value="0.02"/>
                    <measurement group_id="O6" value="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MH CD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06"/>
                    <measurement group_id="O2" value="0.09"/>
                    <measurement group_id="O3" value="0.11"/>
                    <measurement group_id="O4" value="0.05"/>
                    <measurement group_id="O5" value="0.06"/>
                    <measurement group_id="O6" value="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MH CD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08"/>
                    <measurement group_id="O2" value="0.1"/>
                    <measurement group_id="O3" value="0.12"/>
                    <measurement group_id="O4" value="0.07"/>
                    <measurement group_id="O5" value="0.08"/>
                    <measurement group_id="O6" value="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FM PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FM SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FM SCD4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Prevalent Parasitemia, Prevalent Gametocytemia and Prevalent Severe and Moderate Anemia</title>
        <description>Prevalent parasitemia (PP) was defined as a documented P. falciparum asexual parasite density &gt; 0 identified at timing of assessment. Prevalent gametocytemia (PG) was defined as a documented P. falciparum gametocyte density &gt; 0 identified at a cross sectional survey. Prevalent severe anemia (PSA) was defined as a documented hemoglobin &lt; 5.0 g/dL identified at timing of assessment. Prevalent moderate anemia (PMA) was defined as a documented hemoglobin &lt; 8.0 g/dL identified at at timing of assessment. Results presented are uncorrected for the double enrollment of one subject receiving RTS,S/AS01.</description>
        <time_frame>At Month 20 (Booster)</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3. Data was not collected for the participants in the 6-12W groups for the PG category.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Prevalent Parasitemia, Prevalent Gametocytemia and Prevalent Severe and Moderate Anemia</title>
          <description>Prevalent parasitemia (PP) was defined as a documented P. falciparum asexual parasite density &gt; 0 identified at timing of assessment. Prevalent gametocytemia (PG) was defined as a documented P. falciparum gametocyte density &gt; 0 identified at a cross sectional survey. Prevalent severe anemia (PSA) was defined as a documented hemoglobin &lt; 5.0 g/dL identified at timing of assessment. Prevalent moderate anemia (PMA) was defined as a documented hemoglobin &lt; 8.0 g/dL identified at at timing of assessment. Results presented are uncorrected for the double enrollment of one subject receiving RTS,S/AS01.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3. Data was not collected for the participants in the 6-12W groups for the PG category.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4140"/>
                <count group_id="O2" value="3571"/>
                <count group_id="O3" value="2100"/>
                <count group_id="O4" value="1766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4140"/>
                    <count group_id="O2" value="3571"/>
                    <count group_id="O3" value="2100"/>
                    <count group_id="O4" value="1766"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07"/>
                    <measurement group_id="O2" value="0.07"/>
                    <measurement group_id="O3" value="0.11"/>
                    <measurement group_id="O4" value="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4139"/>
                    <count group_id="O2" value="3571"/>
                    <count group_id="O3" value="2097"/>
                    <count group_id="O4" value="1765"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4139"/>
                    <count group_id="O2" value="3571"/>
                    <count group_id="O3" value="2097"/>
                    <count group_id="O4" value="1765"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.04"/>
                    <measurement group_id="O3" value="0.03"/>
                    <measurement group_id="O4" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PG</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4021"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2025"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O3" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Prevalent Parasitemia and Prevalent Severe and Moderate Anemia</title>
        <description>Prevalent parasitemia (PP) was defined as a documented P. falciparum asexual parasite density &gt; 0 identified at timing of assessment. Prevalent severe anemia (PSA) was defined as a documented hemoglobin &lt; 5.0 g/dL identified at timing of assessment. Prevalent moderate anemia (PMA) was defined as a documented hemoglobin &lt; 8.0 g/dL identified at timing of assessment. Analysis was performed on subjects aged 5-17 months at enrollment. Study End (Early) corresponds to children whose Month 32 visit took place after 30 June 2012 and who had one cross-sectional visit at study end. These children's last study visit was relatively earlier, with a median follow-up time of 14 months post Month 32. Study End (Late) corresponds to children whose Month 32 visit took place before (and including) 30 June 2012, and who had 2 cross-sectional visits after Month 32. These children's last study visit was relatively later, with a median follow-up time of 17 months post Month 32).</description>
        <time_frame>At Months 32, 44, at study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category) (early and late)</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period 14 days post Dose 3. Data was not collected for the participants in the 6-12W groups for the PP, PSA, PMA categories at M44, SE (Late).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Prevalent Parasitemia and Prevalent Severe and Moderate Anemia</title>
          <description>Prevalent parasitemia (PP) was defined as a documented P. falciparum asexual parasite density &gt; 0 identified at timing of assessment. Prevalent severe anemia (PSA) was defined as a documented hemoglobin &lt; 5.0 g/dL identified at timing of assessment. Prevalent moderate anemia (PMA) was defined as a documented hemoglobin &lt; 8.0 g/dL identified at timing of assessment. Analysis was performed on subjects aged 5-17 months at enrollment. Study End (Early) corresponds to children whose Month 32 visit took place after 30 June 2012 and who had one cross-sectional visit at study end. These children's last study visit was relatively earlier, with a median follow-up time of 14 months post Month 32. Study End (Late) corresponds to children whose Month 32 visit took place before (and including) 30 June 2012, and who had 2 cross-sectional visits after Month 32. These children's last study visit was relatively later, with a median follow-up time of 17 months post Month 32).</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period 14 days post Dose 3. Data was not collected for the participants in the 6-12W groups for the PP, PSA, PMA categories at M44, SE (Late).</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1935"/>
                <count group_id="O2" value="1967"/>
                <count group_id="O3" value="1979"/>
                <count group_id="O4" value="1637"/>
                <count group_id="O5" value="1656"/>
                <count group_id="O6" value="1648"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PP, Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1935"/>
                    <count group_id="O2" value="1963"/>
                    <count group_id="O3" value="1976"/>
                    <count group_id="O4" value="1635"/>
                    <count group_id="O5" value="1656"/>
                    <count group_id="O6" value="1647"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09"/>
                    <measurement group_id="O2" value="0.1"/>
                    <measurement group_id="O3" value="0.14"/>
                    <measurement group_id="O4" value="0.09"/>
                    <measurement group_id="O5" value="0.11"/>
                    <measurement group_id="O6" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA, Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1934"/>
                    <count group_id="O2" value="1967"/>
                    <count group_id="O3" value="1979"/>
                    <count group_id="O4" value="1637"/>
                    <count group_id="O5" value="1655"/>
                    <count group_id="O6" value="1648"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMA, Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1934"/>
                    <count group_id="O2" value="1967"/>
                    <count group_id="O3" value="1979"/>
                    <count group_id="O4" value="1637"/>
                    <count group_id="O5" value="1655"/>
                    <count group_id="O6" value="1648"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.02"/>
                    <measurement group_id="O5" value="0.04"/>
                    <measurement group_id="O6" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PP, Month 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1039"/>
                    <count group_id="O2" value="1072"/>
                    <count group_id="O3" value="1093"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16"/>
                    <measurement group_id="O2" value="0.17"/>
                    <measurement group_id="O3" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA, Month 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1041"/>
                    <count group_id="O2" value="1072"/>
                    <count group_id="O3" value="1094"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMA, Month 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1041"/>
                    <count group_id="O2" value="1072"/>
                    <count group_id="O3" value="1094"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PP, SE (Early)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="681"/>
                    <count group_id="O2" value="661"/>
                    <count group_id="O3" value="672"/>
                    <count group_id="O4" value="1481"/>
                    <count group_id="O5" value="1472"/>
                    <count group_id="O6" value="1487"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09"/>
                    <measurement group_id="O2" value="0.1"/>
                    <measurement group_id="O3" value="0.14"/>
                    <measurement group_id="O4" value="0.11"/>
                    <measurement group_id="O5" value="0.14"/>
                    <measurement group_id="O6" value="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA, SE (Early)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="681"/>
                    <count group_id="O2" value="661"/>
                    <count group_id="O3" value="672"/>
                    <count group_id="O4" value="1481"/>
                    <count group_id="O5" value="1472"/>
                    <count group_id="O6" value="1486"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMA, SE (Early)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="681"/>
                    <count group_id="O2" value="661"/>
                    <count group_id="O3" value="672"/>
                    <count group_id="O4" value="1481"/>
                    <count group_id="O5" value="1472"/>
                    <count group_id="O6" value="1486"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.03"/>
                    <measurement group_id="O4" value="0.03"/>
                    <measurement group_id="O5" value="0.03"/>
                    <measurement group_id="O6" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PP, SE (Late)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1054"/>
                    <count group_id="O2" value="1059"/>
                    <count group_id="O3" value="1104"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18"/>
                    <measurement group_id="O2" value="0.18"/>
                    <measurement group_id="O3" value="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA, SE (Late)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1053"/>
                    <count group_id="O2" value="1057"/>
                    <count group_id="O3" value="1104"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMA, SE (Late)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1053"/>
                    <count group_id="O2" value="1057"/>
                    <count group_id="O3" value="1104"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Pneumonia, All-cause Hospitalization and Sepsis, as Per Case Definitions Assessed</title>
        <description>Pneumonia case definitions assessed are PCD and SCD 1, 2 and 3. Pneumonia of PCD was defined as cough or difficulty breathing AND tachypnea (≥ 50 breaths per minute &lt; 1 year, ≥ 40 breaths per minute ≥ 1year) AND lower chest wall indrawing. Pneumonia of SCD1 was defined as pneumonia of PCD accompanied by chest X-ray (CXR) consolidation or pleural effusion on x-ray taken within 72 h of admission. Pneumonia of SCD2 was defined as pneumonia of PCD accompanied by consolidation or pleural effusion or other infiltrates on a chest x-ray taken within 72 h of admission. Pneumonia of SCD3 was defined as pneumonia of PCD accompanied by an oxygen saturation &lt; 90%. All-cause hospitalization of PCD was defined as a medical hospitalization of any cause (excludes planned admissions for medical investigation/care or elective surgery and trauma). Sepsis cases were defined as a child with positive blood culture (CD1) or salmonella blood culture (CD2).</description>
        <time_frame>From Month 2.5 to Month 20</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Pneumonia, All-cause Hospitalization and Sepsis, as Per Case Definitions Assessed</title>
          <description>Pneumonia case definitions assessed are PCD and SCD 1, 2 and 3. Pneumonia of PCD was defined as cough or difficulty breathing AND tachypnea (≥ 50 breaths per minute &lt; 1 year, ≥ 40 breaths per minute ≥ 1year) AND lower chest wall indrawing. Pneumonia of SCD1 was defined as pneumonia of PCD accompanied by chest X-ray (CXR) consolidation or pleural effusion on x-ray taken within 72 h of admission. Pneumonia of SCD2 was defined as pneumonia of PCD accompanied by consolidation or pleural effusion or other infiltrates on a chest x-ray taken within 72 h of admission. Pneumonia of SCD3 was defined as pneumonia of PCD accompanied by an oxygen saturation &lt; 90%. All-cause hospitalization of PCD was defined as a medical hospitalization of any cause (excludes planned admissions for medical investigation/care or elective surgery and trauma). Sepsis cases were defined as a child with positive blood culture (CD1) or salmonella blood culture (CD2).</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4557"/>
                <count group_id="O2" value="3996"/>
                <count group_id="O3" value="2328"/>
                <count group_id="O4" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pneumonia PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.04"/>
                    <measurement group_id="O3" value="0.03"/>
                    <measurement group_id="O4" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia SCD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia SCD3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-Cause Hospitalization PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15"/>
                    <measurement group_id="O2" value="0.18"/>
                    <measurement group_id="O3" value="0.19"/>
                    <measurement group_id="O4" value="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis CD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis CD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Fatal Malaria (FM) and All-cause Mortality (ACM) as Per Case Definitions Assessed</title>
        <description>Fatal malaria case definitions assessed were PCD and SCD1. Fatal malaria of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease (defined in a previous outcome measure) with a fatal outcome. Fatal malaria of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease (defined previously) with a fatal outcome. All-cause mortality case definitions assessed were the case definitions (CD) 1 and 2. All-cause mortality of CD1 was defined as a fatality (of any cause) (including mortality in the community and in hospital). All-cause mortality of CD2 was defined as a fatality (medical cause) (including mortality in the community and in hospital), at the exclusion of trauma which may be diagnosed by verbal autopsy. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine.</description>
        <time_frame>From Month 2.5 to Month 20</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Fatal Malaria (FM) and All-cause Mortality (ACM) as Per Case Definitions Assessed</title>
          <description>Fatal malaria case definitions assessed were PCD and SCD1. Fatal malaria of PCD was defined as a case of severe malaria meeting the primary case definition of severe malaria disease (defined in a previous outcome measure) with a fatal outcome. Fatal malaria of SCD1 was defined as a case of severe malaria meeting the secondary case definition 1 severe malaria disease (defined previously) with a fatal outcome. All-cause mortality case definitions assessed were the case definitions (CD) 1 and 2. All-cause mortality of CD1 was defined as a fatality (of any cause) (including mortality in the community and in hospital). All-cause mortality of CD2 was defined as a fatality (medical cause) (including mortality in the community and in hospital), at the exclusion of trauma which may be diagnosed by verbal autopsy. Results presented are uncorrected for double enrollment of one subject in 5-17 months age category receiving GSK257049 vaccine.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4557"/>
                <count group_id="O2" value="3996"/>
                <count group_id="O3" value="2328"/>
                <count group_id="O4" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatal Malaria PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal Malaria SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-cause mortality CD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-cause mortality CD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Pneumonia, All-cause Hospitalization/Mortality and Sepsis, as Per Case Definitions Assessed</title>
        <description>Pneumonia of PCD was defined as cough or difficulty breathing (on history) AND tachypnea (&gt;= 50 breaths per minute &lt; 1 year, &gt;= 40 breaths per minute &gt;= 1year) AND lower chest wall indrawing,SCD1 was defined as pneumonia of PCD accompanied by chest X-ray (CXR) consolidation or pleural effusion on x-ray taken within 72 h of admission,SCD2 was defined as pneumonia of PCD accompanied by consolidation or pleural effusion or other infiltrates on a chest x-ray taken within 72 h of admission,SCD3 was defined as pneumonia of PCD accompanied by an oxygen saturation less than 90%.All-cause hospitalization of PCD was defined as a medical hospitalization of any cause (excluding planned admissions for medical investigation/care or elective surgery and trauma).All-cause mortality of CD1 was defined as a fatality (of any cause),of CD2 defined as a fatality (medical cause).Sepsis of CD1 was defined as a child with positive blood culture;CD2 defined as a child with positive salmonella blood culture.</description>
        <time_frame>From Month 2.5 up to study end (with a median follow-up time post-Dose 1 of 48 months for 5-17M groups and 38 months for 6-12W groups)</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Pneumonia, All-cause Hospitalization/Mortality and Sepsis, as Per Case Definitions Assessed</title>
          <description>Pneumonia of PCD was defined as cough or difficulty breathing (on history) AND tachypnea (&gt;= 50 breaths per minute &lt; 1 year, &gt;= 40 breaths per minute &gt;= 1year) AND lower chest wall indrawing,SCD1 was defined as pneumonia of PCD accompanied by chest X-ray (CXR) consolidation or pleural effusion on x-ray taken within 72 h of admission,SCD2 was defined as pneumonia of PCD accompanied by consolidation or pleural effusion or other infiltrates on a chest x-ray taken within 72 h of admission,SCD3 was defined as pneumonia of PCD accompanied by an oxygen saturation less than 90%.All-cause hospitalization of PCD was defined as a medical hospitalization of any cause (excluding planned admissions for medical investigation/care or elective surgery and trauma).All-cause mortality of CD1 was defined as a fatality (of any cause),of CD2 defined as a fatality (medical cause).Sepsis of CD1 was defined as a child with positive blood culture;CD2 defined as a child with positive salmonella blood culture.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2276"/>
                <count group_id="O2" value="2306"/>
                <count group_id="O3" value="2336"/>
                <count group_id="O4" value="1985"/>
                <count group_id="O5" value="2005"/>
                <count group_id="O6" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All-Cause Hospitalization PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21"/>
                    <measurement group_id="O2" value="0.22"/>
                    <measurement group_id="O3" value="0.24"/>
                    <measurement group_id="O4" value="0.23"/>
                    <measurement group_id="O5" value="0.23"/>
                    <measurement group_id="O6" value="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis CD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.03"/>
                    <measurement group_id="O4" value="0.02"/>
                    <measurement group_id="O5" value="0.02"/>
                    <measurement group_id="O6" value="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis CD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.01"/>
                    <measurement group_id="O5" value="0.02"/>
                    <measurement group_id="O6" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia PCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.03"/>
                    <measurement group_id="O4" value="0.05"/>
                    <measurement group_id="O5" value="0.05"/>
                    <measurement group_id="O6" value="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia SCD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.01"/>
                    <measurement group_id="O5" value="0.01"/>
                    <measurement group_id="O6" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia SCD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.02"/>
                    <measurement group_id="O3" value="0.02"/>
                    <measurement group_id="O4" value="0.03"/>
                    <measurement group_id="O5" value="0.03"/>
                    <measurement group_id="O6" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia SCD3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.01"/>
                    <measurement group_id="O5" value="0.01"/>
                    <measurement group_id="O6" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-Cause Mortality CD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.02"/>
                    <measurement group_id="O5" value="0.02"/>
                    <measurement group_id="O6" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-Cause Mortality CD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01"/>
                    <measurement group_id="O2" value="0.01"/>
                    <measurement group_id="O3" value="0.01"/>
                    <measurement group_id="O4" value="0.02"/>
                    <measurement group_id="O5" value="0.02"/>
                    <measurement group_id="O6" value="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Blood Transfusion, as Per Case Definition Assessed</title>
        <description>Blood transfusion case definition assessed was the case definition 1 (CD1). Blood transfusion of CD1 was defined as a child with inpatient admission with documented blood transfusion.</description>
        <time_frame>From Month 2.5 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Blood Transfusion, as Per Case Definition Assessed</title>
          <description>Blood transfusion case definition assessed was the case definition 1 (CD1). Blood transfusion of CD1 was defined as a child with inpatient admission with documented blood transfusion.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2276"/>
                <count group_id="O2" value="2306"/>
                <count group_id="O3" value="2336"/>
                <count group_id="O4" value="1985"/>
                <count group_id="O5" value="2005"/>
                <count group_id="O6" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.04"/>
                    <measurement group_id="O4" value="0.03"/>
                    <measurement group_id="O5" value="0.03"/>
                    <measurement group_id="O6" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Gender and Overall</title>
        <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T). Analysis was performed on subjects aged 5-17 months and 6-12 weeks at enrollment. Results were presented by gender and overall.</description>
        <time_frame>From Month 2.5 to Month 32</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Gender and Overall</title>
          <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by the presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T). Analysis was performed on subjects aged 5-17 months and 6-12 weeks at enrollment. Results were presented by gender and overall.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2276"/>
                <count group_id="O2" value="2306"/>
                <count group_id="O3" value="2336"/>
                <count group_id="O4" value="1985"/>
                <count group_id="O5" value="2005"/>
                <count group_id="O6" value="2007"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCD Females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1123"/>
                    <count group_id="O2" value="1137"/>
                    <count group_id="O3" value="1167"/>
                    <count group_id="O4" value="967"/>
                    <count group_id="O5" value="976"/>
                    <count group_id="O6" value="1014"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="1.11"/>
                    <measurement group_id="O4" value="0.76"/>
                    <measurement group_id="O5" value="0.79"/>
                    <measurement group_id="O6" value="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1153"/>
                    <count group_id="O2" value="1169"/>
                    <count group_id="O3" value="1169"/>
                    <count group_id="O4" value="1018"/>
                    <count group_id="O5" value="1029"/>
                    <count group_id="O6" value="993"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65"/>
                    <measurement group_id="O2" value="0.81"/>
                    <measurement group_id="O3" value="1.19"/>
                    <measurement group_id="O4" value="0.83"/>
                    <measurement group_id="O5" value="0.96"/>
                    <measurement group_id="O6" value="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCD Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2276"/>
                    <count group_id="O2" value="2306"/>
                    <count group_id="O3" value="2336"/>
                    <count group_id="O4" value="1985"/>
                    <count group_id="O5" value="2005"/>
                    <count group_id="O6" value="2007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68"/>
                    <measurement group_id="O2" value="0.81"/>
                    <measurement group_id="O3" value="1.15"/>
                    <measurement group_id="O4" value="0.8"/>
                    <measurement group_id="O5" value="0.88"/>
                    <measurement group_id="O6" value="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Height, Weight and Mid Upper Arm Circumference for Age Z-score (HAZ, WAZ and MUACZ)</title>
        <description>Anthropometry consisted of length/height for age z-score [HAZ] (children &lt; 2 years length measure and children ≥ 2 years standing height measure), weight for age z-score [WAZ] and mid-upper arm circumference for age z-score [MUACZ] measurements, where a HAZ &lt; -1,5 z-score, indicates growth deficit, while a HAZ between -1,0 and ± 1,0 z-score, indicates normal height. A WAZ ≤ -3 z-score indicates a very low weight for age, a WAZ &gt; -3 and ≤ -2 z-score indicates a low weight for age, a WAZ &gt; - 2 z-score indicates normal weight. A MUACZ &lt; -2 z-score indicates children that are wasted, a MUACZ &lt; - 3 z-score indicates severely wasted children.</description>
        <time_frame>At Month 20 (Booster)</time_frame>
        <population>The analysis was performed on the Intent-to-Treat (ITT) population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Height, Weight and Mid Upper Arm Circumference for Age Z-score (HAZ, WAZ and MUACZ)</title>
          <description>Anthropometry consisted of length/height for age z-score [HAZ] (children &lt; 2 years length measure and children ≥ 2 years standing height measure), weight for age z-score [WAZ] and mid-upper arm circumference for age z-score [MUACZ] measurements, where a HAZ &lt; -1,5 z-score, indicates growth deficit, while a HAZ between -1,0 and ± 1,0 z-score, indicates normal height. A WAZ ≤ -3 z-score indicates a very low weight for age, a WAZ &gt; -3 and ≤ -2 z-score indicates a low weight for age, a WAZ &gt; - 2 z-score indicates normal weight. A MUACZ &lt; -2 z-score indicates children that are wasted, a MUACZ &lt; - 3 z-score indicates severely wasted children.</description>
          <population>The analysis was performed on the Intent-to-Treat (ITT) population, which included all children who received at least one dose of study vaccine.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5948"/>
                <count group_id="O2" value="4358"/>
                <count group_id="O3" value="2974"/>
                <count group_id="O4" value="2179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAZ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5048"/>
                    <count group_id="O2" value="4358"/>
                    <count group_id="O3" value="2974"/>
                    <count group_id="O4" value="2179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1"/>
                    <measurement group_id="O2" value="-1.7" spread="1.1"/>
                    <measurement group_id="O3" value="-1.6" spread="1"/>
                    <measurement group_id="O4" value="-1.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WAZ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5948"/>
                    <count group_id="O2" value="4358"/>
                    <count group_id="O3" value="2974"/>
                    <count group_id="O4" value="2179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1"/>
                    <measurement group_id="O2" value="-0.9" spread="1"/>
                    <measurement group_id="O3" value="-1" spread="1"/>
                    <measurement group_id="O4" value="-0.9" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MUACZ</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5948"/>
                    <count group_id="O2" value="4358"/>
                    <count group_id="O3" value="2974"/>
                    <count group_id="O4" value="2179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.9"/>
                    <measurement group_id="O2" value="-0.1" spread="1"/>
                    <measurement group_id="O3" value="-0.3" spread="0.9"/>
                    <measurement group_id="O4" value="-0.1" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Height, Weight and Mid Upper Arm Circumference for Age Z-score (HAZ, WAZ and MUACZ)</title>
        <description>Anthropometry consisted of length/height for age z-score [HAZ] (children &lt; 2 years length measure and children ≥ 2 years standing height measure), weight for age z-score [WAZ] and mid-upper arm circumference for age z-score [MUACZ] measurements, where a HAZ &lt; -1,5 z-score, indicates growth deficit, while a HAZ between -1,0 and ± 1,0 z-score, indicates normal height. A WAZ ≤ -3 z-score indicates a very low weight for age, a WAZ &gt; -3 and ≤ -2 z-score indicates a low weight for age, a WAZ &gt; - 2 z-score indicates normal weight. A MUACZ &lt; -2 z-score indicates children that are wasted, a MUACZ &lt; - 3 z-score indicates severely wasted children. Note: The early study end refers to children whose last visit in the primary study phase (Month 32) was after 30 June 2012 and who by protocol had one cross-sectional study end and to late study end refers to children whose last visit in the primary study phase (Month 32) was after 30 June 2012 and who by protocol had one cross-sectional study end.</description>
        <time_frame>At Months 32, 44, at study end (early and late) (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine. Data was not collected for the participants in the 6-12W groups for the HAZ, WAZ, MUACZ categories at Month 44 and at Study end Late time frames.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Height, Weight and Mid Upper Arm Circumference for Age Z-score (HAZ, WAZ and MUACZ)</title>
          <description>Anthropometry consisted of length/height for age z-score [HAZ] (children &lt; 2 years length measure and children ≥ 2 years standing height measure), weight for age z-score [WAZ] and mid-upper arm circumference for age z-score [MUACZ] measurements, where a HAZ &lt; -1,5 z-score, indicates growth deficit, while a HAZ between -1,0 and ± 1,0 z-score, indicates normal height. A WAZ ≤ -3 z-score indicates a very low weight for age, a WAZ &gt; -3 and ≤ -2 z-score indicates a low weight for age, a WAZ &gt; - 2 z-score indicates normal weight. A MUACZ &lt; -2 z-score indicates children that are wasted, a MUACZ &lt; - 3 z-score indicates severely wasted children. Note: The early study end refers to children whose last visit in the primary study phase (Month 32) was after 30 June 2012 and who by protocol had one cross-sectional study end and to late study end refers to children whose last visit in the primary study phase (Month 32) was after 30 June 2012 and who by protocol had one cross-sectional study end.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine. Data was not collected for the participants in the 6-12W groups for the HAZ, WAZ, MUACZ categories at Month 44 and at Study end Late time frames.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2382"/>
                <count group_id="O3" value="2392"/>
                <count group_id="O4" value="1726"/>
                <count group_id="O5" value="1731"/>
                <count group_id="O6" value="1725"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAZ, Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2363"/>
                    <count group_id="O2" value="2382"/>
                    <count group_id="O3" value="2392"/>
                    <count group_id="O4" value="1726"/>
                    <count group_id="O5" value="1731"/>
                    <count group_id="O6" value="1725"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.0"/>
                    <measurement group_id="O2" value="-1.4" spread="1.0"/>
                    <measurement group_id="O3" value="-1.4" spread="1.0"/>
                    <measurement group_id="O4" value="-1.5" spread="1.1"/>
                    <measurement group_id="O5" value="-1.4" spread="1.1"/>
                    <measurement group_id="O6" value="-1.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WAZ, Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2363"/>
                    <count group_id="O2" value="2382"/>
                    <count group_id="O3" value="2392"/>
                    <count group_id="O4" value="1726"/>
                    <count group_id="O5" value="1731"/>
                    <count group_id="O6" value="1725"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.9"/>
                    <measurement group_id="O2" value="-1.0" spread="0.9"/>
                    <measurement group_id="O3" value="-1.0" spread="0.9"/>
                    <measurement group_id="O4" value="-0.9" spread="1.0"/>
                    <measurement group_id="O5" value="-0.9" spread="1.0"/>
                    <measurement group_id="O6" value="-0.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MUACZ, Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2363"/>
                    <count group_id="O2" value="2382"/>
                    <count group_id="O3" value="2392"/>
                    <count group_id="O4" value="1726"/>
                    <count group_id="O5" value="1731"/>
                    <count group_id="O6" value="1725"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.9"/>
                    <measurement group_id="O2" value="-0.4" spread="0.9"/>
                    <measurement group_id="O3" value="-0.4" spread="0.8"/>
                    <measurement group_id="O4" value="-0.4" spread="0.9"/>
                    <measurement group_id="O5" value="-0.3" spread="1.0"/>
                    <measurement group_id="O6" value="-0.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAZ, Month 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1275"/>
                    <count group_id="O2" value="1289"/>
                    <count group_id="O3" value="1307"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.0"/>
                    <measurement group_id="O2" value="-1.2" spread="0.9"/>
                    <measurement group_id="O3" value="-1.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WAZ, Month 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1275"/>
                    <count group_id="O2" value="1289"/>
                    <count group_id="O3" value="1307"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.9"/>
                    <measurement group_id="O2" value="-1.0" spread="0.9"/>
                    <measurement group_id="O3" value="-0.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MUACZ, Month 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1275"/>
                    <count group_id="O2" value="1289"/>
                    <count group_id="O3" value="1307"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.8"/>
                    <measurement group_id="O2" value="-0.7" spread="0.9"/>
                    <measurement group_id="O3" value="-0.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAZ, Study end Early</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="774"/>
                    <count group_id="O2" value="755"/>
                    <count group_id="O3" value="768"/>
                    <count group_id="O4" value="1555"/>
                    <count group_id="O5" value="1533"/>
                    <count group_id="O6" value="1549"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.0"/>
                    <measurement group_id="O2" value="-1.3" spread="1.0"/>
                    <measurement group_id="O3" value="-1.3" spread="1.0"/>
                    <measurement group_id="O4" value="-1.4" spread="1.0"/>
                    <measurement group_id="O5" value="-1.4" spread="1.0"/>
                    <measurement group_id="O6" value="-1.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WAZ, Study end Early</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="774"/>
                    <count group_id="O2" value="755"/>
                    <count group_id="O3" value="768"/>
                    <count group_id="O4" value="1555"/>
                    <count group_id="O5" value="1533"/>
                    <count group_id="O6" value="1549"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.8"/>
                    <measurement group_id="O2" value="-1.0" spread="0.8"/>
                    <measurement group_id="O3" value="-1.0" spread="0.8"/>
                    <measurement group_id="O4" value="-0.9" spread="0.9"/>
                    <measurement group_id="O5" value="-0.9" spread="0.9"/>
                    <measurement group_id="O6" value="-0.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MUACZ, Study end Early</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="774"/>
                    <count group_id="O2" value="755"/>
                    <count group_id="O3" value="768"/>
                    <count group_id="O4" value="1555"/>
                    <count group_id="O5" value="1533"/>
                    <count group_id="O6" value="1549"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.9"/>
                    <measurement group_id="O2" value="-0.8" spread="0.9"/>
                    <measurement group_id="O3" value="-0.8" spread="0.8"/>
                    <measurement group_id="O4" value="-0.5" spread="0.9"/>
                    <measurement group_id="O5" value="-0.4" spread="0.9"/>
                    <measurement group_id="O6" value="-0.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAZ, Study end Late</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1290"/>
                    <count group_id="O2" value="1283"/>
                    <count group_id="O3" value="1317"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.9"/>
                    <measurement group_id="O2" value="-1.1" spread="0.9"/>
                    <measurement group_id="O3" value="-1.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WAZ, Study end Late</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1290"/>
                    <count group_id="O2" value="1283"/>
                    <count group_id="O3" value="1317"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.9"/>
                    <measurement group_id="O2" value="-1.0" spread="0.9"/>
                    <measurement group_id="O3" value="-1.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MUACZ, Study end Late</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1290"/>
                    <count group_id="O2" value="1283"/>
                    <count group_id="O3" value="1317"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.8"/>
                    <measurement group_id="O2" value="-0.8" spread="0.9"/>
                    <measurement group_id="O3" value="-0.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Plasmodium Falciparum Circumsporozoite (Anti-CS)</title>
        <description>Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were assessed for the first 200 subjects enrolled in each study center.</description>
        <time_frame>At Day 0 and at Month 3</time_frame>
        <population>The analysis was performed on the ATP population for immunogenicity, which included all first 200 children enrolled in each study center in each age category who received all vaccinations according to the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Plasmodium Falciparum Circumsporozoite (Anti-CS)</title>
          <description>Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were assessed for the first 200 subjects enrolled in each study center.</description>
          <population>The analysis was performed on the ATP population for immunogenicity, which included all first 200 children enrolled in each study center in each age category who received all vaccinations according to the protocol procedures.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1036"/>
                <count group_id="O2" value="1234"/>
                <count group_id="O3" value="529"/>
                <count group_id="O4" value="627"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CS, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1036"/>
                    <count group_id="O2" value="1234"/>
                    <count group_id="O3" value="526"/>
                    <count group_id="O4" value="627"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.4" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="0.4" lower_limit="0.4" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1034"/>
                    <count group_id="O2" value="1221"/>
                    <count group_id="O3" value="529"/>
                    <count group_id="O4" value="627"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="621" lower_limit="591.5" upper_limit="651.9"/>
                    <measurement group_id="O2" value="210.5" lower_limit="198.2" upper_limit="223.6"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS)</title>
        <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were assessed for the first 200 HIV-infected subjects enrolled in each study center. HIV infection was confirmed if present at screening or identified by morbidity surveillance, not infection confirmed by antibody testing after 18 months of age or by PCR, by the time of the analysis of results up to the Month 14 time point for the respective 5-17 months and 6-12 weeks age categories.</description>
        <time_frame>At Day 0 and at Month 3</time_frame>
        <population>The analysis was performed on the HIV-ATP population for immunogenicity, which included all children included in the HIV-ITT population who received all vaccinations according to the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS)</title>
          <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were assessed for the first 200 HIV-infected subjects enrolled in each study center. HIV infection was confirmed if present at screening or identified by morbidity surveillance, not infection confirmed by antibody testing after 18 months of age or by PCR, by the time of the analysis of results up to the Month 14 time point for the respective 5-17 months and 6-12 weeks age categories.</description>
          <population>The analysis was performed on the HIV-ATP population for immunogenicity, which included all children included in the HIV-ITT population who received all vaccinations according to the protocol procedures.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CS, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O4" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.7" lower_limit="137.5" upper_limit="509.6"/>
                    <measurement group_id="O2" value="125.3" lower_limit="58.1" upper_limit="270.3"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.2" upper_limit="1.7"/>
                    <measurement group_id="O4" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS)</title>
        <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL.</description>
        <time_frame>At Months 20, 21 and 32</time_frame>
        <population>The analysis was performed on the ATP population for immunogenicity, which included all first 200 children enrolled in each study center in each age category who received all vaccinations according to the protocol procedures. Data was not collected for the participants in the 5-17M groups for the Manhica site at any given time frame.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS)</title>
          <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL.</description>
          <population>The analysis was performed on the ATP population for immunogenicity, which included all first 200 children enrolled in each study center in each age category who received all vaccinations according to the protocol procedures. Data was not collected for the participants in the 5-17M groups for the Manhica site at any given time frame.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="442"/>
                <count group_id="O2" value="438"/>
                <count group_id="O3" value="426"/>
                <count group_id="O4" value="530"/>
                <count group_id="O5" value="569"/>
                <count group_id="O6" value="554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CS, Agogo - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" lower_limit="24.0" upper_limit="48.3"/>
                    <measurement group_id="O2" value="52.1" lower_limit="41.3" upper_limit="65.7"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                    <measurement group_id="O4" value="5.1" lower_limit="3.4" upper_limit="7.6"/>
                    <measurement group_id="O5" value="5.6" lower_limit="3.8" upper_limit="8.4"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Agogo - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265.0" lower_limit="220.9" upper_limit="317.9"/>
                    <measurement group_id="O2" value="48.3" lower_limit="37.6" upper_limit="61.9"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O4" value="137.6" lower_limit="95.0" upper_limit="199.3"/>
                    <measurement group_id="O5" value="5.3" lower_limit="3.5" upper_limit="8.0"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Agogo - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="52"/>
                    <count group_id="O5" value="53"/>
                    <count group_id="O6" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3" lower_limit="34.8" upper_limit="61.6"/>
                    <measurement group_id="O2" value="28.8" lower_limit="21.8" upper_limit="37.9"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O4" value="14.8" lower_limit="9.5" upper_limit="23.1"/>
                    <measurement group_id="O5" value="2.9" lower_limit="1.9" upper_limit="4.5"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Bagamoyo - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="14.2" upper_limit="49.9"/>
                    <measurement group_id="O2" value="23.1" lower_limit="11.1" upper_limit="47.8"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="6.9" lower_limit="4.8" upper_limit="10.0"/>
                    <measurement group_id="O5" value="7.6" lower_limit="5.1" upper_limit="11.4"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Bagamoyo - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="53"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.6" lower_limit="206.5" upper_limit="455.4"/>
                    <measurement group_id="O2" value="31.8" lower_limit="19.4" upper_limit="52.2"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.2" upper_limit="1.4"/>
                    <measurement group_id="O4" value="169.9" lower_limit="129.8" upper_limit="222.5"/>
                    <measurement group_id="O5" value="7.2" lower_limit="4.5" upper_limit="11.6"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Bagamoyo - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" lower_limit="27.2" upper_limit="73.3"/>
                    <measurement group_id="O2" value="16.9" lower_limit="10.2" upper_limit="27.9"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="14.4" lower_limit="9.6" upper_limit="21.7"/>
                    <measurement group_id="O5" value="3.7" lower_limit="2.4" upper_limit="5.7"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Kilifi - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="56"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" lower_limit="26.3" upper_limit="44.7"/>
                    <measurement group_id="O2" value="33.1" lower_limit="26.3" upper_limit="41.6"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="6.6" lower_limit="4.6" upper_limit="9.6"/>
                    <measurement group_id="O5" value="6.1" lower_limit="4.0" upper_limit="9.4"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Kilifi - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308.4" lower_limit="251.8" upper_limit="377.7"/>
                    <measurement group_id="O2" value="24.3" lower_limit="18.1" upper_limit="32.8"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="229.3" lower_limit="175.4" upper_limit="299.9"/>
                    <measurement group_id="O5" value="5.3" lower_limit="3.4" upper_limit="8.2"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Kilifi - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="39"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" lower_limit="45.7" upper_limit="77.2"/>
                    <measurement group_id="O2" value="14.9" lower_limit="11.0" upper_limit="20.2"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O4" value="19.8" lower_limit="14.1" upper_limit="27.8"/>
                    <measurement group_id="O5" value="2.8" lower_limit="1.8" upper_limit="4.4"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Kintampo - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="52"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" lower_limit="37.2" upper_limit="69.5"/>
                    <measurement group_id="O2" value="36.6" lower_limit="26.4" upper_limit="50.7"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O4" value="3.8" lower_limit="2.5" upper_limit="5.8"/>
                    <measurement group_id="O5" value="3.7" lower_limit="2.5" upper_limit="5.6"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Kintampo - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="50"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.8" lower_limit="188.9" upper_limit="377.0"/>
                    <measurement group_id="O2" value="41.2" lower_limit="31.2" upper_limit="54.6"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O4" value="128.8" lower_limit="95.7" upper_limit="173.4"/>
                    <measurement group_id="O5" value="3.2" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Kintampo - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" lower_limit="55.2" upper_limit="90.9"/>
                    <measurement group_id="O2" value="20.2" lower_limit="14.3" upper_limit="28.5"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O4" value="13.3" lower_limit="8.1" upper_limit="21.9"/>
                    <measurement group_id="O5" value="2.2" lower_limit="1.4" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Kombewa - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="29.9" upper_limit="53.0"/>
                    <measurement group_id="O2" value="46.6" lower_limit="33.2" upper_limit="65.3"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                    <measurement group_id="O4" value="5.5" lower_limit="3.6" upper_limit="8.4"/>
                    <measurement group_id="O5" value="8.7" lower_limit="5.8" upper_limit="13.0"/>
                    <measurement group_id="O6" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Kombewa - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="51"/>
                    <count group_id="O6" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308.5" lower_limit="252.4" upper_limit="377.0"/>
                    <measurement group_id="O2" value="37.1" lower_limit="26.7" upper_limit="51.5"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.3" upper_limit="0.4"/>
                    <measurement group_id="O4" value="146.3" lower_limit="96.6" upper_limit="221.6"/>
                    <measurement group_id="O5" value="9.2" lower_limit="6.0" upper_limit="14.2"/>
                    <measurement group_id="O6" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Kombewa - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="46"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" lower_limit="40.3" upper_limit="71.7"/>
                    <measurement group_id="O2" value="19.8" lower_limit="14.1" upper_limit="27.7"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                    <measurement group_id="O4" value="8.3" lower_limit="4.8" upper_limit="14.3"/>
                    <measurement group_id="O5" value="4.3" lower_limit="2.8" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.4" lower_limit="0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Korogwe - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="52"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" lower_limit="21.4" upper_limit="40.4"/>
                    <measurement group_id="O2" value="28.2" lower_limit="22.5" upper_limit="35.3"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="7.9" lower_limit="5.3" upper_limit="11.8"/>
                    <measurement group_id="O5" value="8.1" lower_limit="5.2" upper_limit="12.7"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Korogwe - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305.6" lower_limit="266.4" upper_limit="350.5"/>
                    <measurement group_id="O2" value="27.1" lower_limit="20.7" upper_limit="35.5"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O4" value="178.3" lower_limit="141.2" upper_limit="225.1"/>
                    <measurement group_id="O5" value="7.6" lower_limit="4.8" upper_limit="11.9"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Korogwe - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" lower_limit="37.5" upper_limit="59.9"/>
                    <measurement group_id="O2" value="16.8" lower_limit="13.1" upper_limit="21.7"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O4" value="19.6" lower_limit="13.0" upper_limit="29.6"/>
                    <measurement group_id="O5" value="4.9" lower_limit="3.0" upper_limit="7.9"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Lambarene - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="5.8" upper_limit="11.6"/>
                    <measurement group_id="O2" value="11.1" lower_limit="7.0" upper_limit="17.6"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O4" value="7.7" lower_limit="5.1" upper_limit="11.6"/>
                    <measurement group_id="O5" value="8.3" lower_limit="5.8" upper_limit="12.1"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Lambarene - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.6" lower_limit="155.1" upper_limit="267.3"/>
                    <measurement group_id="O2" value="10.6" lower_limit="6.6" upper_limit="16.8"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O4" value="251.3" lower_limit="184.8" upper_limit="341.7"/>
                    <measurement group_id="O5" value="7.4" lower_limit="5.0" upper_limit="10.8"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Lambarene - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="15.6" upper_limit="33.9"/>
                    <measurement group_id="O2" value="5.9" lower_limit="3.6" upper_limit="9.9"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O4" value="21.0" lower_limit="13.9" upper_limit="31.7"/>
                    <measurement group_id="O5" value="4.1" lower_limit="2.9" upper_limit="5.8"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Lilongwe - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9" lower_limit="28.6" upper_limit="73.8"/>
                    <measurement group_id="O2" value="22.2" lower_limit="11.2" upper_limit="44.0"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.2" upper_limit="0.7"/>
                    <measurement group_id="O4" value="5.1" lower_limit="3.2" upper_limit="8.3"/>
                    <measurement group_id="O5" value="7.4" lower_limit="4.7" upper_limit="11.5"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Lilongwe - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="44"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285.0" lower_limit="228.5" upper_limit="355.4"/>
                    <measurement group_id="O2" value="17.0" lower_limit="8.1" upper_limit="35.7"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O4" value="126.1" lower_limit="92.7" upper_limit="171.5"/>
                    <measurement group_id="O5" value="8.0" lower_limit="5.2" upper_limit="12.1"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Lilongwe - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" lower_limit="28.8" upper_limit="72.3"/>
                    <measurement group_id="O2" value="12.7" lower_limit="6.4" upper_limit="25.3"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O4" value="15.4" lower_limit="9.3" upper_limit="25.4"/>
                    <measurement group_id="O5" value="4.5" lower_limit="3.1" upper_limit="6.6"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Nanoro - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="69"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2" lower_limit="43.4" upper_limit="75.4"/>
                    <measurement group_id="O2" value="61.8" lower_limit="46.3" upper_limit="82.4"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="2.7" lower_limit="1.7" upper_limit="4.4"/>
                    <measurement group_id="O5" value="3.2" lower_limit="2.1" upper_limit="4.7"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Nanoro - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="520.5" lower_limit="443.4" upper_limit="611.1"/>
                    <measurement group_id="O2" value="71.1" lower_limit="54.8" upper_limit="92.3"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O4" value="163.2" lower_limit="121.4" upper_limit="219.4"/>
                    <measurement group_id="O5" value="3.1" lower_limit="2.0" upper_limit="4.6"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Nanoro - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="66"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" lower_limit="55.2" upper_limit="86.9"/>
                    <measurement group_id="O2" value="35.0" lower_limit="25.7" upper_limit="47.9"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="11.9" lower_limit="7.4" upper_limit="19.2"/>
                    <measurement group_id="O5" value="2.8" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.4" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Siaya - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" lower_limit="18.4" upper_limit="44.0"/>
                    <measurement group_id="O2" value="32.8" lower_limit="21.6" upper_limit="50.1"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                    <measurement group_id="O4" value="7.0" lower_limit="4.2" upper_limit="11.5"/>
                    <measurement group_id="O5" value="8.9" lower_limit="5.5" upper_limit="14.2"/>
                    <measurement group_id="O6" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Siaya - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398.1" lower_limit="324.6" upper_limit="488.2"/>
                    <measurement group_id="O2" value="36.4" lower_limit="22.6" upper_limit="58.6"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O4" value="171.5" lower_limit="109.8" upper_limit="267.9"/>
                    <measurement group_id="O5" value="8.4" lower_limit="5.2" upper_limit="13.6"/>
                    <measurement group_id="O6" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Siaya - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" lower_limit="41.4" upper_limit="75.3"/>
                    <measurement group_id="O2" value="21.7" lower_limit="13.4" upper_limit="35.1"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O4" value="23.6" lower_limit="14.2" upper_limit="39.1"/>
                    <measurement group_id="O5" value="5.5" lower_limit="3.3" upper_limit="9.2"/>
                    <measurement group_id="O6" value="0.5" lower_limit="0.4" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Manhica - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="46"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="12.3" lower_limit="8.4" upper_limit="18.1"/>
                    <measurement group_id="O5" value="14.7" lower_limit="10.0" upper_limit="21.5"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Manhica - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="260.2" lower_limit="176.4" upper_limit="383.8"/>
                    <measurement group_id="O5" value="12.3" lower_limit="7.7" upper_limit="19.5"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Manhica - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="25.4" lower_limit="14.8" upper_limit="43.5"/>
                    <measurement group_id="O5" value="6.8" lower_limit="4.0" upper_limit="11.5"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Overall sites - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="442"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="426"/>
                    <count group_id="O4" value="530"/>
                    <count group_id="O5" value="569"/>
                    <count group_id="O6" value="554"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" lower_limit="30.7" upper_limit="38.6"/>
                    <measurement group_id="O2" value="35.4" lower_limit="31.7" upper_limit="39.5"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="5.9" lower_limit="5.2" upper_limit="6.7"/>
                    <measurement group_id="O5" value="6.6" lower_limit="5.8" upper_limit="7.5"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Overall sites - Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="409"/>
                    <count group_id="O4" value="503"/>
                    <count group_id="O5" value="544"/>
                    <count group_id="O6" value="519"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318.2" lower_limit="295.1" upper_limit="343.0"/>
                    <measurement group_id="O2" value="34.2" lower_limit="30.5" upper_limit="38.3"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="169.9" lower_limit="153.8" upper_limit="187.7"/>
                    <measurement group_id="O5" value="6.2" lower_limit="5.4" upper_limit="7.0"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Overall sites - Month 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="414"/>
                    <count group_id="O2" value="408"/>
                    <count group_id="O3" value="393"/>
                    <count group_id="O4" value="478"/>
                    <count group_id="O5" value="515"/>
                    <count group_id="O6" value="501"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="47.8" upper_limit="57.6"/>
                    <measurement group_id="O2" value="19.3" lower_limit="17.2" upper_limit="21.8"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="15.9" lower_limit="13.8" upper_limit="18.3"/>
                    <measurement group_id="O5" value="3.7" lower_limit="3.3" upper_limit="4.2"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS)</title>
        <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results for this endpoint were assessed for Agogo, Lilongwe and Siaya sites.</description>
        <time_frame>At Month 44 and at study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
        <population>The analysis was performed on the ATP population for immunogenicity, which included all first 200 children enrolled in each study center in each age category who received all vaccinations according to the protocol procedures. Data was not collected for the participants in the 6-12W groups at M44.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS)</title>
          <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results for this endpoint were assessed for Agogo, Lilongwe and Siaya sites.</description>
          <population>The analysis was performed on the ATP population for immunogenicity, which included all first 200 children enrolled in each study center in each age category who received all vaccinations according to the protocol procedures. Data was not collected for the participants in the 6-12W groups at M44.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="103"/>
                <count group_id="O6" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CS, Agogo - Month 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" lower_limit="20.1" upper_limit="38.1"/>
                    <measurement group_id="O2" value="17.9" lower_limit="13.5" upper_limit="23.6"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Agogo - Study end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="16.7" upper_limit="32.3"/>
                    <measurement group_id="O2" value="17.2" lower_limit="12.7" upper_limit="23.3"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O4" value="6.1" lower_limit="3.2" upper_limit="11.4"/>
                    <measurement group_id="O5" value="2.1" lower_limit="1.3" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Lilongwe - Month 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="21.4" upper_limit="43.5"/>
                    <measurement group_id="O2" value="8.5" lower_limit="4.5" upper_limit="15.9"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Lilongwe - Study end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" lower_limit="18.3" upper_limit="39.5"/>
                    <measurement group_id="O2" value="7.2" lower_limit="4.1" upper_limit="12.5"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O4" value="10.9" lower_limit="6.3" upper_limit="18.7"/>
                    <measurement group_id="O5" value="2.8" lower_limit="1.8" upper_limit="4.2"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Siaya - Month 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" lower_limit="29.7" upper_limit="57.9"/>
                    <measurement group_id="O2" value="21.2" lower_limit="14.0" upper_limit="32.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.4" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Siaya - Study end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="19.4" upper_limit="38.9"/>
                    <measurement group_id="O2" value="15.8" lower_limit="10.2" upper_limit="24.4"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.3" upper_limit="0.6"/>
                    <measurement group_id="O4" value="10.4" lower_limit="6.1" upper_limit="17.7"/>
                    <measurement group_id="O5" value="3.3" lower_limit="1.9" upper_limit="5.6"/>
                    <measurement group_id="O6" value="0.4" lower_limit="0.3" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Overall - Month 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" lower_limit="26.9" upper_limit="40.3"/>
                    <measurement group_id="O2" value="16.8" lower_limit="13.5" upper_limit="21.0"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Overall - Study end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="101"/>
                    <count group_id="O5" value="103"/>
                    <count group_id="O6" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" lower_limit="20.6" upper_limit="31.2"/>
                    <measurement group_id="O2" value="14.4" lower_limit="11.4" upper_limit="18.1"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                    <measurement group_id="O4" value="8.9" lower_limit="6.5" upper_limit="12.3"/>
                    <measurement group_id="O5" value="2.6" lower_limit="2.0" upper_limit="3.4"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS), by Tertile</title>
        <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were presented by tertiles of anti-CS responses in the first 200 participants per site, based on subjects assessed for vaccine efficacy results.</description>
        <time_frame>At Month 3</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS), by Tertile</title>
          <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were presented by tertiles of anti-CS responses in the first 200 participants per site, based on subjects assessed for vaccine efficacy results.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CS, Tertile 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.15" lower_limit="238.2" upper_limit="292.9"/>
                    <measurement group_id="O2" value="78.45" lower_limit="69.4" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Tertile 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="613.79" lower_limit="598.3" upper_limit="629.7"/>
                    <measurement group_id="O2" value="230.68" lower_limit="224.7" upper_limit="236.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Tertile 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1351.41" lower_limit="1276.3" upper_limit="1431"/>
                    <measurement group_id="O2" value="592.65" lower_limit="557.8" upper_limit="629.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Across Tertiles</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="639"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="603.77" lower_limit="563.6" upper_limit="646.8"/>
                    <measurement group_id="O2" value="220.9" lower_limit="204.1" upper_limit="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Tertile</title>
        <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T). RaCPFMI was calculated by tertile of anti-CS response post primary vaccination pooled across sites, on subjects in GSK257049-Menjugate Groups (5-17M; 6-12W) and Comparator Groups (5-17M; 6-12W), taking into account the first 200 participants per site.</description>
        <time_frame>From Month 2.5 to Month 32</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Tertile</title>
          <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T). RaCPFMI was calculated by tertile of anti-CS response post primary vaccination pooled across sites, on subjects in GSK257049-Menjugate Groups (5-17M; 6-12W) and Comparator Groups (5-17M; 6-12W), taking into account the first 200 participants per site.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="565"/>
                <count group_id="O3" value="214"/>
                <count group_id="O4" value="677"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tertile 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="565"/>
                    <count group_id="O3" value="212"/>
                    <count group_id="O4" value="677"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68"/>
                    <measurement group_id="O2" value="1.21"/>
                    <measurement group_id="O3" value="1.29"/>
                    <measurement group_id="O4" value="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="565"/>
                    <count group_id="O3" value="214"/>
                    <count group_id="O4" value="677"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78"/>
                    <measurement group_id="O2" value="1.21"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="565"/>
                    <count group_id="O3" value="213"/>
                    <count group_id="O4" value="677"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03"/>
                    <measurement group_id="O2" value="1.21"/>
                    <measurement group_id="O3" value="0.58"/>
                    <measurement group_id="O4" value="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS), by Tertile</title>
        <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were presented by tertiles of anti-CS responses in the first 200 participants per site, based on subjects assessed for vaccine efficacy results.</description>
        <time_frame>At Month 21</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against P. Falciparum Circumsporozoite (Anti-CS), by Tertile</title>
          <description>Anti-CS antibody concentrations were determined by ELISA and presented as geometric mean concentrations (GMCs), expressed in EL.U/mL. The seropositivity cut-off for the endpoint was a GMC value ≥ 0.5 EL.U/mL. Results were presented by tertiles of anti-CS responses in the first 200 participants per site, based on subjects assessed for vaccine efficacy results.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="465"/>
                <count group_id="O2" value="546"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CS, Tertile 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.15" lower_limit="123.5" upper_limit="154.5"/>
                    <measurement group_id="O2" value="47.99" lower_limit="41.2" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Tertile 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="156"/>
                    <count group_id="O2" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311.35" lower_limit="303.4" upper_limit="319.6"/>
                    <measurement group_id="O2" value="194.85" lower_limit="189.9" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Tertile 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="675.24" lower_limit="632.8" upper_limit="720.5"/>
                    <measurement group_id="O2" value="479.44" lower_limit="446.8" upper_limit="514.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CS, Across Tertiles</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="465"/>
                    <count group_id="O2" value="546"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307.93" lower_limit="286.2" upper_limit="331.3"/>
                    <measurement group_id="O2" value="165.31" lower_limit="150" upper_limit="182.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Tertile</title>
        <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T). RaCPFMI was calculated by tertile of anti-CS response post booster vaccination pooled across sites, on subjects in R3R (5-17M; 6-12W) (or R3R below) and C3C (5-17M; 6-12W) (or C3C below) groups taking into account the first 200 participants per site.</description>
        <time_frame>From Booster at Month 20 to Month 32</time_frame>
        <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Episodes of Clinical P. Falciparum Malaria Infection (CPFMI) of Primary Case Definition (PCD), by Tertile</title>
          <description>CPFMI of PCD = episode of malaria for which PFAP &gt; 5000 parasites/µL accompanied by presence of fever (axillary temperature ≥ 37.5°C at time of presentation) AND occurring in a child unwell brought for treatment to a healthcare facility OR a case of malaria meeting the PCD of severe malaria disease. Time to all episodes of CPFMI is expressed as a rate of all CPFMI (RaCPFMI), that is, person-year rate in each group (n/T). RaCPFMI was calculated by tertile of anti-CS response post booster vaccination pooled across sites, on subjects in R3R (5-17M; 6-12W) (or R3R below) and C3C (5-17M; 6-12W) (or C3C below) groups taking into account the first 200 participants per site.</description>
          <population>The analysis was performed on the ATP population for efficacy, which included all children who received all vaccinations according to protocol procedures and contributed to the time at risk in the follow-up period starting 14 days post Dose 3.</population>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="479"/>
                <count group_id="O3" value="420"/>
                <count group_id="O4" value="594"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tertile 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="420"/>
                    <count group_id="O4" value="594"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68"/>
                    <measurement group_id="O2" value="1.21"/>
                    <measurement group_id="O3" value="0.99"/>
                    <measurement group_id="O4" value="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="156"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="362"/>
                    <count group_id="O4" value="594"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68"/>
                    <measurement group_id="O2" value="1.21"/>
                    <measurement group_id="O3" value="0.84"/>
                    <measurement group_id="O4" value="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tertile 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="276"/>
                    <count group_id="O4" value="594"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77"/>
                    <measurement group_id="O2" value="1.21"/>
                    <measurement group_id="O3" value="0.64"/>
                    <measurement group_id="O4" value="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Hepatitis B Surface Antigen (Anti-HBs)</title>
        <description>Antibody concentrations assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU/mL). The seropositivity and seroprotection cut-offs were ≥ 10 and 100 mIU/mL, respectively. Results were assessed for the first 200 subjects in each center.</description>
        <time_frame>At Day 0 and at Month 3</time_frame>
        <population>The analysis was performed on the ATP population for immunogenicity, which included all first 200 children enrolled in each study center, for each age category who received all vaccinations according to the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Hepatitis B Surface Antigen (Anti-HBs)</title>
          <description>Antibody concentrations assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU/mL). The seropositivity and seroprotection cut-offs were ≥ 10 and 100 mIU/mL, respectively. Results were assessed for the first 200 subjects in each center.</description>
          <population>The analysis was performed on the ATP population for immunogenicity, which included all first 200 children enrolled in each study center, for each age category who received all vaccinations according to the protocol procedures.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
                <count group_id="O2" value="1213"/>
                <count group_id="O3" value="526"/>
                <count group_id="O4" value="627"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HBs, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1017"/>
                    <count group_id="O2" value="1120"/>
                    <count group_id="O3" value="515"/>
                    <count group_id="O4" value="561"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.3" lower_limit="148" upper_limit="186.8"/>
                    <measurement group_id="O2" value="8.6" lower_limit="8" upper_limit="9.3"/>
                    <measurement group_id="O3" value="168.6" lower_limit="142.8" upper_limit="199.2"/>
                    <measurement group_id="O4" value="8.5" lower_limit="7.7" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HBs, Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1029"/>
                    <count group_id="O2" value="1213"/>
                    <count group_id="O3" value="526"/>
                    <count group_id="O4" value="627"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81567.7" lower_limit="75442.7" upper_limit="88189.9"/>
                    <measurement group_id="O2" value="13674.3" lower_limit="12811.5" upper_limit="14595.3"/>
                    <measurement group_id="O3" value="127.5" lower_limit="108.8" upper_limit="149.4"/>
                    <measurement group_id="O4" value="728.8" lower_limit="643.6" upper_limit="825.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Hepatitis B Surface Antigen</title>
        <description>Antibody concentrations as assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in mIU/mL. The seropositivity and seroprotection cut-offs were ≥ 10 and 100 mIU/mL, respectively. Results were assessed for the first 200 HIV-infected subjects enrolled in each study center. HIV infection was confirmed if present at screening or identified by morbidity surveillance, not infection confirmed by antibody testing after 18 months of age or by PCR, by the time of the analysis of results up to the Month 14 time point for the respective 5-17 months and 6-12 weeks age categories.</description>
        <time_frame>At Day 0 and at Month 3</time_frame>
        <population>The analysis was performed on the HIV-ATP population for immunogenicity, which included all children included in the HIV-ITT population who received all vaccinations according to the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Hepatitis B Surface Antigen</title>
          <description>Antibody concentrations as assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in mIU/mL. The seropositivity and seroprotection cut-offs were ≥ 10 and 100 mIU/mL, respectively. Results were assessed for the first 200 HIV-infected subjects enrolled in each study center. HIV infection was confirmed if present at screening or identified by morbidity surveillance, not infection confirmed by antibody testing after 18 months of age or by PCR, by the time of the analysis of results up to the Month 14 time point for the respective 5-17 months and 6-12 weeks age categories.</description>
          <population>The analysis was performed on the HIV-ATP population for immunogenicity, which included all children included in the HIV-ITT population who received all vaccinations according to the protocol procedures.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HBs, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="43.8" upper_limit="222"/>
                    <measurement group_id="O2" value="7.5" lower_limit="4.8" upper_limit="11.6"/>
                    <measurement group_id="O3" value="63.6" lower_limit="19.4" upper_limit="208.4"/>
                    <measurement group_id="O4" value="5" lower_limit="5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HBs, Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37476.5" lower_limit="17766" upper_limit="79054.9"/>
                    <measurement group_id="O2" value="1996.2" lower_limit="561.6" upper_limit="7095.8"/>
                    <measurement group_id="O3" value="37.1" lower_limit="9.1" upper_limit="151.9"/>
                    <measurement group_id="O4" value="197.2" lower_limit="7.7" upper_limit="5081.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Hepatitis B Surface Antigen (Anti-HBs)</title>
        <description>Antibody concentrations as assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in mIU/mL. The seropositivity and seroprotection cut-offs were ≥ 6.2 and 100 mIU/mL, respectively. Results were assessed for the first 200 subjects in each center.</description>
        <time_frame>At Months 20 and 21</time_frame>
        <population>The analysis was performed on the ATP population for HBs immunogenicity post booster, which included the first 200 children enrolled in Korogwe, Lamberene and Lilongwe study centers in each age category who received the booster dose of GSK257049 vaccine and all vaccinations according to the protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Hepatitis B Surface Antigen (Anti-HBs)</title>
          <description>Antibody concentrations as assessed by ELISA, were presented as geometric mean concentrations (GMCs), and expressed in mIU/mL. The seropositivity and seroprotection cut-offs were ≥ 6.2 and 100 mIU/mL, respectively. Results were assessed for the first 200 subjects in each center.</description>
          <population>The analysis was performed on the ATP population for HBs immunogenicity post booster, which included the first 200 children enrolled in Korogwe, Lamberene and Lilongwe study centers in each age category who received the booster dose of GSK257049 vaccine and all vaccinations according to the protocol procedures.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HBs, Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5068.5" lower_limit="3711.3" upper_limit="6922"/>
                    <measurement group_id="O2" value="1532.5" lower_limit="1240.6" upper_limit="1893.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HBs, Month 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95206.4" lower_limit="72395.4" upper_limit="125204.9"/>
                    <measurement group_id="O2" value="116458.1" lower_limit="86865.7" upper_limit="156131.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Titers Against Poliomyelitis (Anti-polio) Type 1, 2 and 3</title>
        <description>Anti-Polio 1, 2 and 3 antibody titers were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was an antibody titer ≥ 1:8.</description>
        <time_frame>At Day 0 and at Month 3</time_frame>
        <population>The ATP population for Polio Sabin™ immunogenicity included all subjects from the ATP population for immunogenicity (minus those who received ≥ 2 doses of Polio Sabin™ vaccine prior to Dose 1 of study vaccine, or who received at least one dose of a polio vaccine in co-administration with the study vaccine before one month post Dose 3 blood sample.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O2">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titers Against Poliomyelitis (Anti-polio) Type 1, 2 and 3</title>
          <description>Anti-Polio 1, 2 and 3 antibody titers were presented as geometric mean titers (GMTs). The seroprotection cut-off for the assay was an antibody titer ≥ 1:8.</description>
          <population>The ATP population for Polio Sabin™ immunogenicity included all subjects from the ATP population for immunogenicity (minus those who received ≥ 2 doses of Polio Sabin™ vaccine prior to Dose 1 of study vaccine, or who received at least one dose of a polio vaccine in co-administration with the study vaccine before one month post Dose 3 blood sample.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="931"/>
                <count group_id="O2" value="474"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Polio 1, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="928"/>
                    <count group_id="O2" value="469"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" lower_limit="41.7" upper_limit="53.8"/>
                    <measurement group_id="O2" value="43.3" lower_limit="36.2" upper_limit="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1, Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="913"/>
                    <count group_id="O2" value="464"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.9" lower_limit="295.2" upper_limit="379.8"/>
                    <measurement group_id="O2" value="417.6" lower_limit="351.4" upper_limit="496.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="928"/>
                    <count group_id="O2" value="468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" lower_limit="34.6" upper_limit="43.2"/>
                    <measurement group_id="O2" value="40.3" lower_limit="34.2" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2, Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="913"/>
                    <count group_id="O2" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372.1" lower_limit="334.5" upper_limit="414.0"/>
                    <measurement group_id="O2" value="450.8" lower_limit="393.9" upper_limit="516.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="931"/>
                    <count group_id="O2" value="474"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="8.6" upper_limit="10.3"/>
                    <measurement group_id="O2" value="9.1" lower_limit="8.0" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3, Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="913"/>
                    <count group_id="O2" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="71.0" upper_limit="90.1"/>
                    <measurement group_id="O2" value="95.9" lower_limit="82.0" upper_limit="112.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms included pain, redness and swelling. Any = the incidence of a particular symptom, regardless of intensity grade. Grade 3 pain = cried when limb was moved, spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.</description>
        <time_frame>During the 7-day (Days 0-6) post-primary vaccination period following each dose and across doses</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine and had their symptom sheets filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms included pain, redness and swelling. Any = the incidence of a particular symptom, regardless of intensity grade. Grade 3 pain = cried when limb was moved, spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine and had their symptom sheets filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1479"/>
                <count group_id="O2" value="721"/>
                <count group_id="O3" value="1462"/>
                <count group_id="O4" value="738"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="435"/>
                    <measurement group_id="O4" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="176"/>
                    <measurement group_id="O4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="227"/>
                    <measurement group_id="O4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="1412"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="383"/>
                    <measurement group_id="O4" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="1412"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="1412"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="124"/>
                    <measurement group_id="O4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="1412"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="1412"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="228"/>
                    <measurement group_id="O4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="1412"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="699"/>
                    <count group_id="O3" value="1378"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="345"/>
                    <measurement group_id="O4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="699"/>
                    <count group_id="O3" value="1378"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="699"/>
                    <count group_id="O3" value="1378"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="699"/>
                    <count group_id="O3" value="1378"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="699"/>
                    <count group_id="O3" value="1378"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="185"/>
                    <measurement group_id="O4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="699"/>
                    <count group_id="O3" value="1378"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="705"/>
                    <measurement group_id="O4" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="292"/>
                    <measurement group_id="O4" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="427"/>
                    <measurement group_id="O4" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="721"/>
                    <count group_id="O3" value="1462"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) post-primary vaccination period following each dose and across doses</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine and had their symptom sheets filled in.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine and had their symptom sheets filled in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1479"/>
                <count group_id="O2" value="1462"/>
                <count group_id="O3" value="721"/>
                <count group_id="O4" value="738"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="164"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="370"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="226"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385"/>
                    <measurement group_id="O2" value="459"/>
                    <measurement group_id="O3" value="108"/>
                    <measurement group_id="O4" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="326"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="289"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503"/>
                    <measurement group_id="O2" value="411"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1435"/>
                    <count group_id="O2" value="1412"/>
                    <count group_id="O3" value="708"/>
                    <count group_id="O4" value="721"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267"/>
                    <measurement group_id="O2" value="278"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="287"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="457"/>
                    <measurement group_id="O2" value="429"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1407"/>
                    <count group_id="O2" value="1378"/>
                    <count group_id="O3" value="699"/>
                    <count group_id="O4" value="710"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                    <measurement group_id="O2" value="280"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drowsiness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="285"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="369"/>
                    <measurement group_id="O2" value="574"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="363"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398"/>
                    <measurement group_id="O2" value="243"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="897"/>
                    <measurement group_id="O2" value="839"/>
                    <measurement group_id="O3" value="235"/>
                    <measurement group_id="O4" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Across doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1479"/>
                    <count group_id="O2" value="1462"/>
                    <count group_id="O3" value="721"/>
                    <count group_id="O4" value="738"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547"/>
                    <measurement group_id="O2" value="598"/>
                    <measurement group_id="O3" value="110"/>
                    <measurement group_id="O4" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms included pain, redness and swelling. Any = the incidence of a particular symptom, regardless of intensity grade. Grade 3 pain = cried when limb was moved, spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.</description>
        <time_frame>During the 7-day (Days 0-6) post-booster vaccination period</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms included pain, redness and swelling. Any = the incidence of a particular symptom, regardless of intensity grade. Grade 3 pain = cried when limb was moved, spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="641"/>
                <count group_id="O2" value="639"/>
                <count group_id="O3" value="633"/>
                <count group_id="O4" value="608"/>
                <count group_id="O5" value="625"/>
                <count group_id="O6" value="621"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="59"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>During the 7-day (Days 0-6) post-booster vaccination period</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were drowsiness, irritability, loss of appetite, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="641"/>
                <count group_id="O2" value="639"/>
                <count group_id="O3" value="633"/>
                <count group_id="O4" value="608"/>
                <count group_id="O5" value="625"/>
                <count group_id="O6" value="621"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="152"/>
                    <measurement group_id="O5" value="52"/>
                    <measurement group_id="O6" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Doses With Seizures by Diagnostic Certainty Level</title>
        <description>Diagnostic certainty levels included: Level 1- Witnessed sudden loss of consciousness and generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations; Level 2- History of unconsciousness and generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations; Level 3- History of unconsciousness and other generalized motor manifestations; Level 4- Reported generalized convulsive seizure with insufficient evidence to meet the case definition; Level 5- Not a case of generalized convulsive seizure.</description>
        <time_frame>During the 7-day (Days 0-6) post-booster vaccination period, at Month 20 + 7 Day (Days 0-6)</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Doses With Seizures by Diagnostic Certainty Level</title>
          <description>Diagnostic certainty levels included: Level 1- Witnessed sudden loss of consciousness and generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations; Level 2- History of unconsciousness and generalized, tonic, clonic, tonic-clonic, or atonic motor manifestations; Level 3- History of unconsciousness and other generalized motor manifestations; Level 4- Reported generalized convulsive seizure with insufficient evidence to meet the case definition; Level 5- Not a case of generalized convulsive seizure.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Doses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2447"/>
                <count group_id="O2" value="2472"/>
                <count group_id="O3" value="2473"/>
                <count group_id="O4" value="1825"/>
                <count group_id="O5" value="1837"/>
                <count group_id="O6" value="1827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Level 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Level 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Level 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Level 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Level 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Mucocutaneous Changes (All Levels)</title>
        <description>Levels of mucocutaneous changes reported were: cutaneous and mucosal change; cutaneous only change; mucosal only change; cutaneous change focused on the nappy/diaper area. Mucocutaneous changes results calculated based on the first 200 subjects in the 6-12 weeks age category in each study center were enrolled, and with available data (i.e. who received a booster dose).</description>
        <time_frame>During the 30-day (Days 0-29) post-booster vaccination</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Mucocutaneous Changes (All Levels)</title>
          <description>Levels of mucocutaneous changes reported were: cutaneous and mucosal change; cutaneous only change; mucosal only change; cutaneous change focused on the nappy/diaper area. Mucocutaneous changes results calculated based on the first 200 subjects in the 6-12 weeks age category in each study center were enrolled, and with available data (i.e. who received a booster dose).</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="617"/>
                <count group_id="O3" value="614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Meningitis and Encephalitis Serious Adverse Events (SAEs)</title>
        <description>Meningitis and encephalitis SAEs included: meningitis/encephalitis; meningitis/encephalitis viral; meningism; meningitis haemophilus; meningitis meningococcal; meningitis pneumococcal; meningitis tuberculous; encephalomyelitis.</description>
        <time_frame>At Month 0 until study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Meningitis and Encephalitis Serious Adverse Events (SAEs)</title>
          <description>Meningitis and encephalitis SAEs included: meningitis/encephalitis; meningitis/encephalitis viral; meningism; meningitis haemophilus; meningitis meningococcal; meningitis pneumococcal; meningitis tuberculous; encephalomyelitis.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2976"/>
                <count group_id="O2" value="2972"/>
                <count group_id="O3" value="2974"/>
                <count group_id="O4" value="2180"/>
                <count group_id="O5" value="2178"/>
                <count group_id="O6" value="2179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Meningitis and Encephalitis SAEs</title>
        <description>Meningitis and encephalitis SAEs included: meningitis/encephalitis; meningitis haemophilus; meningitis meningococcal; meningitis tuberculous; encephalomyelitis.</description>
        <time_frame>From Booster up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Meningitis and Encephalitis SAEs</title>
          <description>Meningitis and encephalitis SAEs included: meningitis/encephalitis; meningitis haemophilus; meningitis meningococcal; meningitis tuberculous; encephalomyelitis.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2681"/>
                <count group_id="O2" value="2719"/>
                <count group_id="O3" value="2702"/>
                <count group_id="O4" value="1966"/>
                <count group_id="O5" value="1996"/>
                <count group_id="O6" value="1976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Potential Immune-mediated Disorders (pIMDs)</title>
        <description>Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
        <time_frame>From Month 0 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any Potential Immune-mediated Disorders (pIMDs)</title>
          <description>Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2976"/>
                <count group_id="O2" value="2972"/>
                <count group_id="O3" value="2974"/>
                <count group_id="O4" value="2180"/>
                <count group_id="O5" value="2178"/>
                <count group_id="O6" value="2179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Unsolicited AEs were calculated based on the first 200 subjects enrolled in each study center.</description>
        <time_frame>Within the 30-day (Days 0-29) post-primary vaccination period</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited Adverse Events (AEs)</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Unsolicited AEs were calculated based on the first 200 subjects enrolled in each study center.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1479"/>
                <count group_id="O2" value="1462"/>
                <count group_id="O3" value="721"/>
                <count group_id="O4" value="738"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1273"/>
                    <measurement group_id="O2" value="1161"/>
                    <measurement group_id="O3" value="626"/>
                    <measurement group_id="O4" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the first 200 subjects enrolled in each study center.</description>
        <time_frame>Within the 30-day (Days 0-29) post-primary vaccination period</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the first 200 subjects enrolled in each study center.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3997"/>
                <count group_id="O2" value="4358"/>
                <count group_id="O3" value="2003"/>
                <count group_id="O4" value="2179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399"/>
                    <measurement group_id="O2" value="578"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited AEs</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Unsolicited AEs were calculated based on the first 200 subjects enrolled in each study center.</description>
        <time_frame>Within the 30-day (days 0-29) post-booster vaccination period</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited AEs</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Unsolicited AEs were calculated based on the first 200 subjects enrolled in each study center.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="641"/>
                <count group_id="O2" value="639"/>
                <count group_id="O3" value="633"/>
                <count group_id="O4" value="608"/>
                <count group_id="O5" value="625"/>
                <count group_id="O6" value="621"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="205"/>
                    <measurement group_id="O3" value="215"/>
                    <measurement group_id="O4" value="231"/>
                    <measurement group_id="O5" value="239"/>
                    <measurement group_id="O6" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center, who were reported with HIV infected status ((HIV status either as per general medical history taken at screening or as identified by morbidity surveillance).</description>
        <time_frame>Within the 30-day (Days 0-29) post-primary and post-booster vaccination period in HIV-infected children</time_frame>
        <population>The analysis was performed on the HIV-ITT population, which included all children who received at least one dose of GSK257049 vaccine and were identified as HIV-infected, that is, confirmed to be HIV-infected via identification as positive for HIV by Polymerase Chain Reaction (PCR), or by antibody at 18 months or older.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 Group</title>
            <description>Pooled group between GSK257049 [5-17M] Group and GSK257049 [6-12W] Group.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 -GSK257049 Group</title>
            <description>Pooled group between GSK257049 -GSK257049 [5-17M] Group and GSK257049 -GSK257049 [6-12W] Group.</description>
          </group>
          <group group_id="O3">
            <title>GSK257049 - Menjugate Group</title>
            <description>Pooled group between GSK257049 - Menjugate [5-17M] Group and GSK257049 - Menjugate [6-12W] Group.</description>
          </group>
          <group group_id="O4">
            <title>Comparator Group</title>
            <description>Pooled Group between VeroRab Comparator [5-17M] Group and Menjugate Comparator [6-12W] Group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center, who were reported with HIV infected status ((HIV status either as per general medical history taken at screening or as identified by morbidity surveillance).</description>
          <population>The analysis was performed on the HIV-ITT population, which included all children who received at least one dose of GSK257049 vaccine and were identified as HIV-infected, that is, confirmed to be HIV-infected via identification as positive for HIV by Polymerase Chain Reaction (PCR), or by antibody at 18 months or older.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s), post-primary vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE(s), post-booster vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal in the Low-weight (LW) and Very Low-weight (VLW) Category</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center, who were reported with HIV infected status ((HIV status either as per general medical history taken at screening or as identified by morbidity surveillance). Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
        <time_frame>Within the 30-day (Days 0-29) post-primary vaccination period in HIV-infected children</time_frame>
        <population>The analysis was performed on the HIV-ITT population, which included low-weight and very low-weight children who received at least one dose of GSK257049 vaccine and were identified as HIV-infected, that is, confirmed to be HIV-infected via identification as positive for HIV by Polymerase Chain Reaction (PCR), or by antibody at 18 months or older.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited AEs Related to or Leading to Vaccination Withdrawal in the Low-weight (LW) and Very Low-weight (VLW) Category</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center, who were reported with HIV infected status ((HIV status either as per general medical history taken at screening or as identified by morbidity surveillance). Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
          <population>The analysis was performed on the HIV-ITT population, which included low-weight and very low-weight children who received at least one dose of GSK257049 vaccine and were identified as HIV-infected, that is, confirmed to be HIV-infected via identification as positive for HIV by Polymerase Chain Reaction (PCR), or by antibody at 18 months or older.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="695"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="364"/>
                <count group_id="O4" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s), in LW</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="695"/>
                    <count group_id="O2" value="221"/>
                    <count group_id="O3" value="364"/>
                    <count group_id="O4" value="126"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE(s), in VLW</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="147"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited AEs Related to Vaccination in the Low-weight (LW) and Very Low-weight (VLW) Category</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center. Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
        <time_frame>Within the 30-day (Days 0-29) post-booster vaccination period</time_frame>
        <population>The analysis was performed on a subset of subjects from the ITT population, which included low-weight (LW) and very low-weight (VLW) children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited AEs Related to Vaccination in the Low-weight (LW) and Very Low-weight (VLW) Category</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Related = AE assessed by the investigator as related to the vaccination. Unsolicited AEs were calculated based on the subgroup of the first 200 subjects enrolled in each study center. Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
          <population>The analysis was performed on a subset of subjects from the ITT population, which included low-weight (LW) and very low-weight (VLW) children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="297"/>
                <count group_id="O3" value="293"/>
                <count group_id="O4" value="230"/>
                <count group_id="O5" value="208"/>
                <count group_id="O6" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s) in LW</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="297"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="230"/>
                    <count group_id="O5" value="208"/>
                    <count group_id="O6" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE(s) in VLW</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                    <count group_id="O6" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From Month 0 up to Month 14</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5948"/>
                <count group_id="O2" value="4358"/>
                <count group_id="O3" value="2974"/>
                <count group_id="O4" value="2179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1040"/>
                    <measurement group_id="O2" value="782"/>
                    <measurement group_id="O3" value="634"/>
                    <measurement group_id="O4" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>During the 30-day (Days 0-29) post-primary vaccination period</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5948"/>
                <count group_id="O2" value="4358"/>
                <count group_id="O3" value="2974"/>
                <count group_id="O4" value="2179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312"/>
                    <measurement group_id="O2" value="192"/>
                    <measurement group_id="O3" value="181"/>
                    <measurement group_id="O4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adversee Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From Month 0 up to Month 20</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adversee Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5948"/>
                <count group_id="O2" value="4358"/>
                <count group_id="O3" value="2974"/>
                <count group_id="O4" value="2179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1108"/>
                    <measurement group_id="O2" value="959"/>
                    <measurement group_id="O3" value="676"/>
                    <measurement group_id="O4" value="503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From Booster (at Month 20) up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2681"/>
                <count group_id="O2" value="2719"/>
                <count group_id="O3" value="2702"/>
                <count group_id="O4" value="1966"/>
                <count group_id="O5" value="1996"/>
                <count group_id="O6" value="1976"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="316"/>
                    <measurement group_id="O3" value="287"/>
                    <measurement group_id="O4" value="180"/>
                    <measurement group_id="O5" value="193"/>
                    <measurement group_id="O6" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From Month 0 up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
        <population>The analysis was performed, across age categories for which groups were pooled from the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed, across age categories for which groups were pooled from the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2976"/>
                <count group_id="O2" value="2972"/>
                <count group_id="O3" value="2974"/>
                <count group_id="O4" value="2180"/>
                <count group_id="O5" value="2178"/>
                <count group_id="O6" value="2179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720"/>
                    <measurement group_id="O2" value="752"/>
                    <measurement group_id="O3" value="846"/>
                    <measurement group_id="O4" value="580"/>
                    <measurement group_id="O5" value="602"/>
                    <measurement group_id="O6" value="619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>Within the 30-day (Days 0-29) post-booster vaccination period</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2447"/>
                <count group_id="O2" value="2472"/>
                <count group_id="O3" value="2473"/>
                <count group_id="O4" value="1825"/>
                <count group_id="O5" value="1837"/>
                <count group_id="O6" value="1827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From Month 0 up to Booster (Month 20), from Month 0 up to study end and from Month 20 up to study end</time_frame>
        <population>The analysis was performed on a subset of subjects from the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 -GSK257049 Group</title>
            <description>Pooled group between GSK257049 -GSK257049 [5-17M] Group and GSK257049 -GSK257049 [6-12W] Group.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate Group</title>
            <description>Pooled group between GSK257049 - Menjugate [5-17M] Group and GSK257049 - Menjugate [6-12W] Group.</description>
          </group>
          <group group_id="O3">
            <title>Comparator Group</title>
            <description>Pooled Group between VeroRab Comparator [5-17M] Group and Menjugate Comparator [6-12W] Group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on a subset of subjects from the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s), Month 0 - Month 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE(s), Month 0 - Study end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE(s), Month 20 - Study end</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Low-weight (LW) Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2.</description>
        <time_frame>From Month 0 up to Month 20</time_frame>
        <population>The analysis was performed on the ITT population, which included low weight (LW) children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Low-weight (LW) Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2.</description>
          <population>The analysis was performed on the ITT population, which included low weight (LW) children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="695"/>
                <count group_id="O2" value="221"/>
                <count group_id="O3" value="364"/>
                <count group_id="O4" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Low-weight (LW) Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2.</description>
        <time_frame>From Booster (Month 20) up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
        <population>The analysis was performed on a subset of subjects from the ITT population, which included low weight (LW) children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Low-weight (LW) Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was &gt; -3 and ≤ -2.</description>
          <population>The analysis was performed on a subset of subjects from the ITT population, which included low weight (LW) children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="297"/>
                <count group_id="O4" value="232"/>
                <count group_id="O5" value="211"/>
                <count group_id="O6" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Very Low-weight (VLW) Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
        <time_frame>From Month 0 up to Month 20</time_frame>
        <population>The analysis was performed on a subset of subjects from the ITT population, which included very-low weight (VLW) children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Very Low-weight (VLW) Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
          <population>The analysis was performed on a subset of subjects from the ITT population, which included very-low weight (VLW) children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Very Low-weight Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
        <time_frame>From Booster (Month 20) up to study end (median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)]</time_frame>
        <population>The analysis was performed on a subset of subjects from the ITT population, which included very-low weight (VLW) children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Very Low-weight Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Very low-weight subjects were defined as subjects whose weight for age z-score (WAZ) was ≤ -3.</description>
          <population>The analysis was performed on a subset of subjects from the ITT population, which included very-low weight (VLW) children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Fatal Outcomes, by Gender</title>
        <description>Mortality was presented as overall mortality (up to Month 20 and up to study end), mortality due to severe malaria as per secondary case definition(SCD), cerebral malaria as per secondary case definition (SCD), meningitis, fatal all-cause traumas and fatal malaria. SCD= Plasmodium falciparum malaria &gt; 5000 parasites/mcL and 1 or more markers of severe malaria (prostration, respiratory distress, Blantyre score ≤ 2, seizures 2 or more, hypoglycemia &lt; 2.2 mmol/L, acidosis BE ≤ -10.0 mmol/L,lactate ≥ 5.0 mmol/L, anemia &lt; 5.0 g/dL.</description>
        <time_frame>From Month 0 up to study end (SE - median follow-up time of 48 months post-Dose 1 for 5-17 months age category and of 38 months post-Dose 1 for 6-12 weeks age category)</time_frame>
        <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK257049 - GSK257049 [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of the same GSK257049 vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O2">
            <title>GSK257049 - Menjugate [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O3">
            <title>VeroRab Comparator [5-17M] Group</title>
            <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
          </group>
          <group group_id="O4">
            <title>GSK257049 -GSK257049 [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of the GSK257049 and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O5">
            <title>GSK257049 - Menjugate [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
          <group group_id="O6">
            <title>Menjugate Comparator [6-12W] Group</title>
            <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Fatal Outcomes, by Gender</title>
          <description>Mortality was presented as overall mortality (up to Month 20 and up to study end), mortality due to severe malaria as per secondary case definition(SCD), cerebral malaria as per secondary case definition (SCD), meningitis, fatal all-cause traumas and fatal malaria. SCD= Plasmodium falciparum malaria &gt; 5000 parasites/mcL and 1 or more markers of severe malaria (prostration, respiratory distress, Blantyre score ≤ 2, seizures 2 or more, hypoglycemia &lt; 2.2 mmol/L, acidosis BE ≤ -10.0 mmol/L,lactate ≥ 5.0 mmol/L, anemia &lt; 5.0 g/dL.</description>
          <population>The analysis was performed on the ITT population, which included all children who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1509"/>
                <count group_id="O2" value="1500"/>
                <count group_id="O3" value="1503"/>
                <count group_id="O4" value="1116"/>
                <count group_id="O5" value="1118"/>
                <count group_id="O6" value="1100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Mortality (M0-M20), Females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1467"/>
                    <count group_id="O2" value="1500"/>
                    <count group_id="O3" value="1503"/>
                    <count group_id="O4" value="1064"/>
                    <count group_id="O5" value="1060"/>
                    <count group_id="O6" value="1100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Mortality (M0-SE), Females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1467"/>
                    <count group_id="O2" value="1500"/>
                    <count group_id="O3" value="1503"/>
                    <count group_id="O4" value="1064"/>
                    <count group_id="O5" value="1060"/>
                    <count group_id="O6" value="1100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Mortality (M0-M20), Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1509"/>
                    <count group_id="O2" value="1472"/>
                    <count group_id="O3" value="1471"/>
                    <count group_id="O4" value="1116"/>
                    <count group_id="O5" value="1118"/>
                    <count group_id="O6" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Mortality (M0-SE), Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1509"/>
                    <count group_id="O2" value="1472"/>
                    <count group_id="O3" value="1471"/>
                    <count group_id="O4" value="1116"/>
                    <count group_id="O5" value="1118"/>
                    <count group_id="O6" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Malaria SCD, All, Females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1467"/>
                    <count group_id="O2" value="1500"/>
                    <count group_id="O3" value="1503"/>
                    <count group_id="O4" value="1064"/>
                    <count group_id="O5" value="1060"/>
                    <count group_id="O6" value="1100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="57"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Malaria SCD, All, Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1509"/>
                    <count group_id="O2" value="1472"/>
                    <count group_id="O3" value="1471"/>
                    <count group_id="O4" value="1116"/>
                    <count group_id="O5" value="1118"/>
                    <count group_id="O6" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="134"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Malaria SCD, Fatal, Females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1467"/>
                    <count group_id="O2" value="1500"/>
                    <count group_id="O3" value="1503"/>
                    <count group_id="O4" value="1064"/>
                    <count group_id="O5" value="1060"/>
                    <count group_id="O6" value="1100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Malaria SCD, Fatal, Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1509"/>
                    <count group_id="O2" value="1472"/>
                    <count group_id="O3" value="1471"/>
                    <count group_id="O4" value="1116"/>
                    <count group_id="O5" value="1118"/>
                    <count group_id="O6" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cerebral Malaria SCD, All, Females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1467"/>
                    <count group_id="O2" value="1500"/>
                    <count group_id="O3" value="1503"/>
                    <count group_id="O4" value="1064"/>
                    <count group_id="O5" value="1060"/>
                    <count group_id="O6" value="1100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cerebral Malaria SCD, All, Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1509"/>
                    <count group_id="O2" value="1472"/>
                    <count group_id="O3" value="1471"/>
                    <count group_id="O4" value="1116"/>
                    <count group_id="O5" value="1118"/>
                    <count group_id="O6" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cerebral Malaria SCD, Fatal, Females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1467"/>
                    <count group_id="O2" value="1500"/>
                    <count group_id="O3" value="1503"/>
                    <count group_id="O4" value="1064"/>
                    <count group_id="O5" value="1060"/>
                    <count group_id="O6" value="1100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cerebral Malaria SCD, Fatal, Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1509"/>
                    <count group_id="O2" value="1472"/>
                    <count group_id="O3" value="1471"/>
                    <count group_id="O4" value="1116"/>
                    <count group_id="O5" value="1118"/>
                    <count group_id="O6" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis, All, Females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1467"/>
                    <count group_id="O2" value="1500"/>
                    <count group_id="O3" value="1503"/>
                    <count group_id="O4" value="1064"/>
                    <count group_id="O5" value="1060"/>
                    <count group_id="O6" value="1100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis, All, Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1509"/>
                    <count group_id="O2" value="1472"/>
                    <count group_id="O3" value="1471"/>
                    <count group_id="O4" value="1116"/>
                    <count group_id="O5" value="1118"/>
                    <count group_id="O6" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis, Fatal, Females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1467"/>
                    <count group_id="O2" value="1500"/>
                    <count group_id="O3" value="1503"/>
                    <count group_id="O4" value="1064"/>
                    <count group_id="O5" value="1060"/>
                    <count group_id="O6" value="1100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis, Fatal, Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1509"/>
                    <count group_id="O2" value="1472"/>
                    <count group_id="O3" value="1471"/>
                    <count group_id="O4" value="1116"/>
                    <count group_id="O5" value="1118"/>
                    <count group_id="O6" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal All-Cause Traumas, Females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1467"/>
                    <count group_id="O2" value="1500"/>
                    <count group_id="O3" value="1503"/>
                    <count group_id="O4" value="1064"/>
                    <count group_id="O5" value="1060"/>
                    <count group_id="O6" value="1100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal All-Cause Traumas, Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1509"/>
                    <count group_id="O2" value="1472"/>
                    <count group_id="O3" value="1471"/>
                    <count group_id="O4" value="1116"/>
                    <count group_id="O5" value="1118"/>
                    <count group_id="O6" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal Malaria, Females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1467"/>
                    <count group_id="O2" value="1500"/>
                    <count group_id="O3" value="1503"/>
                    <count group_id="O4" value="1064"/>
                    <count group_id="O5" value="1060"/>
                    <count group_id="O6" value="1100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal Malaria, Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1509"/>
                    <count group_id="O2" value="1472"/>
                    <count group_id="O3" value="1471"/>
                    <count group_id="O4" value="1116"/>
                    <count group_id="O5" value="1118"/>
                    <count group_id="O6" value="1079"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination periods; Unsolicited AEs: during the 30-day (Days 0-29) post-vaccination periods; SAEs: from Day 0 up to study end (median follow-up of 48 months for 5-17M subjects and of 38 months for 6-12W subjects).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK257049 [5-17M] Group</title>
          <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
        </group>
        <group group_id="E2">
          <title>GSK257049 [6-12W] Group</title>
          <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin™ vaccines or a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 20. All vaccines have been administered intramuscularly in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
        </group>
        <group group_id="E3">
          <title>VeroRab Comparator [5-17M] Group</title>
          <description>Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab® vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.</description>
        </group>
        <group group_id="E4">
          <title>Menjugate Comparator [6-12W] Group</title>
          <description>Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate® vaccine co-administered with Polio Sabin™ and Tritanrix HepB™/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate® and Polio Sabin™ vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate® vaccine); anterolateral right thigh (Tritanrix HepB™/Hib vaccine), except for the Polio Sabin™ vaccine, which has been given orally.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="5948"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="4358"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="2974"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1475" subjects_at_risk="5948"/>
                <counts group_id="E2" subjects_affected="1186" subjects_at_risk="4358"/>
                <counts group_id="E3" subjects_affected="848" subjects_at_risk="2974"/>
                <counts group_id="E4" subjects_affected="622" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="329" subjects_affected="277" subjects_at_risk="5948"/>
                <counts group_id="E2" events="258" subjects_affected="198" subjects_at_risk="4358"/>
                <counts group_id="E3" events="246" subjects_affected="198" subjects_at_risk="2974"/>
                <counts group_id="E4" events="138" subjects_affected="116" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Intravascular haemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Leukaemoid reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cerebral palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Choledochal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Congenital megacolon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Fallot's tetralogy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Glucose-6-phosphate dehydrogenase deficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5948"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Sickle cell anaemia with crisis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="5948"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="4358"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="2974"/>
                <counts group_id="E4" events="10" subjects_affected="5" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Trisomy 21</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Urethral valves</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="5948"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="4358"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="2974"/>
                <counts group_id="E4" events="18" subjects_affected="18" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Stress ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="5948"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="4358"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="2974"/>
                <counts group_id="E4" events="18" subjects_affected="18" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="5948"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="4358"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2974"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Aids dementia complex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5948"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Bone tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="42" subjects_affected="38" subjects_at_risk="5948"/>
                <counts group_id="E2" events="33" subjects_affected="32" subjects_at_risk="4358"/>
                <counts group_id="E3" events="24" subjects_affected="18" subjects_at_risk="2974"/>
                <counts group_id="E4" events="26" subjects_affected="24" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="5948"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="4358"/>
                <counts group_id="E3" events="22" subjects_affected="21" subjects_at_risk="2974"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="76" subjects_affected="68" subjects_at_risk="5948"/>
                <counts group_id="E2" events="60" subjects_affected="54" subjects_at_risk="4358"/>
                <counts group_id="E3" events="42" subjects_affected="40" subjects_at_risk="2974"/>
                <counts group_id="E4" events="36" subjects_affected="34" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Bullous impetigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Burkholderia cepacia complex sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="5948"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="4358"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2974"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cellulitis pharyngeal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Central nervous system viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cerebral malaria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cholera</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="5948"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="4358"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="2974"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Encephalomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="335" subjects_affected="302" subjects_at_risk="5948"/>
                <counts group_id="E2" events="379" subjects_affected="333" subjects_at_risk="4358"/>
                <counts group_id="E3" events="192" subjects_affected="177" subjects_at_risk="2974"/>
                <counts group_id="E4" events="192" subjects_affected="171" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis escherichia coli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5948"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis shigella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Gastrointestinal candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Haemophilus sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Helminthic infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4358"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hepatitis a</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hepatitis b</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hepatitis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hiv associated nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hiv infection</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="5948"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="4358"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="2974"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hiv infection who clinical stage ii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hiv infection who clinical stage iii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hiv infection who clinical stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5948"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4358"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Injection site cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Listeria sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="5948"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="4358"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="2974"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5948"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4358"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Ludwig angina</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Lymph node abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Lymphadenitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="850" subjects_affected="639" subjects_at_risk="5948"/>
                <counts group_id="E2" events="525" subjects_affected="392" subjects_at_risk="4358"/>
                <counts group_id="E3" events="533" subjects_affected="423" subjects_at_risk="2974"/>
                <counts group_id="E4" events="303" subjects_affected="236" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5948"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="4358"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2974"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="5948"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Meningitis haemophilus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Meningitis meningococcal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Meningitis salmonella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Moraxella infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Mumps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Mycobacterium ulcerans infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4358"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="5948"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="4358"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="2974"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Plasmodium ovale infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pneumococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5948"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="4358"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2974"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="532" subjects_affected="417" subjects_at_risk="5948"/>
                <counts group_id="E2" events="547" subjects_affected="424" subjects_at_risk="4358"/>
                <counts group_id="E3" events="287" subjects_affected="223" subjects_at_risk="2974"/>
                <counts group_id="E4" events="286" subjects_affected="202" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="5948"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="4358"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pyomyositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Rabies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Rubella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Salmonella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" events="73" subjects_affected="70" subjects_at_risk="5948"/>
                <counts group_id="E2" events="63" subjects_affected="60" subjects_at_risk="4358"/>
                <counts group_id="E3" events="42" subjects_affected="42" subjects_at_risk="2974"/>
                <counts group_id="E4" events="40" subjects_affected="37" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Schistosomiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="61" subjects_affected="60" subjects_at_risk="5948"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="4358"/>
                <counts group_id="E3" events="46" subjects_affected="43" subjects_at_risk="2974"/>
                <counts group_id="E4" events="15" subjects_affected="13" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="5948"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5948"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Taeniasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4358"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Trichiniasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5948"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4358"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2974"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="74" subjects_affected="68" subjects_at_risk="5948"/>
                <counts group_id="E2" events="52" subjects_affected="50" subjects_at_risk="4358"/>
                <counts group_id="E3" events="45" subjects_affected="43" subjects_at_risk="2974"/>
                <counts group_id="E4" events="24" subjects_affected="24" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="47" subjects_affected="45" subjects_at_risk="5948"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="4358"/>
                <counts group_id="E3" events="29" subjects_affected="28" subjects_at_risk="2974"/>
                <counts group_id="E4" events="23" subjects_affected="22" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Accidental poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Bronchitis chemical</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Burns first degree</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5948"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Chemical injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Crush injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Disinfectant poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Eye contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5948"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Fractured skull depressed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Greenstick fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Herbal toxicity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Human bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Penis injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Petroleum distillate poisoning</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pneumonitis chemical</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5948"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4358"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Sciatic nerve injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Snake bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="5948"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="4358"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="2974"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Vaccination failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="5948"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4358"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="2974"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Kwashiorkor</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="5948"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="4358"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="2974"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="58" subjects_affected="54" subjects_at_risk="5948"/>
                <counts group_id="E2" events="58" subjects_affected="50" subjects_at_risk="4358"/>
                <counts group_id="E3" events="25" subjects_affected="21" subjects_at_risk="2974"/>
                <counts group_id="E4" events="21" subjects_affected="19" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Marasmus</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="5948"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="4358"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2974"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Underweight</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Dactylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Rickets</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute promyelocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Inflammatory pseudotumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Langerhans' cell histiocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arachnoid cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cerebellar ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="122" subjects_affected="102" subjects_at_risk="5948"/>
                <counts group_id="E2" events="98" subjects_affected="78" subjects_at_risk="4358"/>
                <counts group_id="E3" events="64" subjects_affected="58" subjects_at_risk="2974"/>
                <counts group_id="E4" events="45" subjects_affected="32" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Encephalomalacia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="5948"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="466" subjects_affected="344" subjects_at_risk="5948"/>
                <counts group_id="E2" events="248" subjects_affected="191" subjects_at_risk="4358"/>
                <counts group_id="E3" events="221" subjects_affected="166" subjects_at_risk="2974"/>
                <counts group_id="E4" events="127" subjects_affected="103" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Meningism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Mental retardation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Speech disorder developmental</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Neurodevelopmental disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoeic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="5948"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4358"/>
                <counts group_id="E3" events="19" subjects_affected="8" subjects_at_risk="2974"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4358"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2974"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5948"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4358"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2974"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Stevens-johnson syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Child abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Sexual abuse</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5948"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4358"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5948"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4358"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2974"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2179"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5948"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4358"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2974"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="2179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1410" subjects_at_risk="1479"/>
                <counts group_id="E2" subjects_affected="1360" subjects_at_risk="1462"/>
                <counts group_id="E3" subjects_affected="664" subjects_at_risk="721"/>
                <counts group_id="E4" subjects_affected="691" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="226" subjects_affected="196" subjects_at_risk="1479"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1462"/>
                <counts group_id="E3" events="107" subjects_affected="92" subjects_at_risk="721"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="148" subjects_affected="136" subjects_at_risk="1479"/>
                <counts group_id="E2" events="195" subjects_affected="149" subjects_at_risk="1462"/>
                <counts group_id="E3" events="74" subjects_affected="65" subjects_at_risk="721"/>
                <counts group_id="E4" events="97" subjects_affected="80" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="688" subjects_affected="493" subjects_at_risk="1479"/>
                <counts group_id="E2" events="1251" subjects_affected="729" subjects_at_risk="1462"/>
                <counts group_id="E3" events="165" subjects_affected="132" subjects_at_risk="721"/>
                <counts group_id="E4" events="571" subjects_affected="348" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1971" subjects_affected="1028" subjects_at_risk="1479"/>
                <counts group_id="E2" events="1852" subjects_affected="966" subjects_at_risk="1462"/>
                <counts group_id="E3" events="416" subjects_affected="306" subjects_at_risk="721"/>
                <counts group_id="E4" events="660" subjects_affected="408" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="491" subjects_affected="352" subjects_at_risk="1479"/>
                <counts group_id="E2" events="713" subjects_affected="456" subjects_at_risk="1462"/>
                <counts group_id="E3" events="192" subjects_affected="138" subjects_at_risk="721"/>
                <counts group_id="E4" events="407" subjects_affected="272" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="92" subjects_affected="83" subjects_at_risk="1479"/>
                <counts group_id="E2" events="80" subjects_affected="69" subjects_at_risk="1462"/>
                <counts group_id="E3" events="41" subjects_affected="37" subjects_at_risk="721"/>
                <counts group_id="E4" events="36" subjects_affected="33" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="135" subjects_affected="126" subjects_at_risk="1479"/>
                <counts group_id="E2" events="147" subjects_affected="139" subjects_at_risk="1462"/>
                <counts group_id="E3" events="77" subjects_affected="74" subjects_at_risk="721"/>
                <counts group_id="E4" events="87" subjects_affected="81" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="435" subjects_affected="368" subjects_at_risk="1479"/>
                <counts group_id="E2" events="339" subjects_affected="257" subjects_at_risk="1462"/>
                <counts group_id="E3" events="188" subjects_affected="159" subjects_at_risk="721"/>
                <counts group_id="E4" events="207" subjects_affected="150" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="422" subjects_affected="305" subjects_at_risk="1479"/>
                <counts group_id="E2" events="249" subjects_affected="199" subjects_at_risk="1462"/>
                <counts group_id="E3" events="289" subjects_affected="207" subjects_at_risk="721"/>
                <counts group_id="E4" events="141" subjects_affected="108" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1479"/>
                <counts group_id="E2" events="82" subjects_affected="73" subjects_at_risk="1462"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E4" events="42" subjects_affected="41" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="200" subjects_affected="175" subjects_at_risk="1479"/>
                <counts group_id="E2" events="94" subjects_affected="87" subjects_at_risk="1462"/>
                <counts group_id="E3" events="84" subjects_affected="72" subjects_at_risk="721"/>
                <counts group_id="E4" events="36" subjects_affected="33" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="139" subjects_affected="123" subjects_at_risk="1479"/>
                <counts group_id="E2" events="183" subjects_affected="166" subjects_at_risk="1462"/>
                <counts group_id="E3" events="59" subjects_affected="52" subjects_at_risk="721"/>
                <counts group_id="E4" events="109" subjects_affected="94" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1006" subjects_affected="683" subjects_at_risk="1479"/>
                <counts group_id="E2" events="1014" subjects_affected="655" subjects_at_risk="1462"/>
                <counts group_id="E3" events="493" subjects_affected="343" subjects_at_risk="721"/>
                <counts group_id="E4" events="503" subjects_affected="344" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="126" subjects_affected="111" subjects_at_risk="1479"/>
                <counts group_id="E2" events="111" subjects_affected="90" subjects_at_risk="1462"/>
                <counts group_id="E3" events="69" subjects_affected="60" subjects_at_risk="721"/>
                <counts group_id="E4" events="55" subjects_affected="49" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="609" subjects_affected="444" subjects_at_risk="1479"/>
                <counts group_id="E2" events="412" subjects_affected="281" subjects_at_risk="1462"/>
                <counts group_id="E3" events="190" subjects_affected="151" subjects_at_risk="721"/>
                <counts group_id="E4" events="158" subjects_affected="114" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="364" subjects_affected="272" subjects_at_risk="1479"/>
                <counts group_id="E2" events="475" subjects_affected="302" subjects_at_risk="1462"/>
                <counts group_id="E3" events="115" subjects_affected="87" subjects_at_risk="721"/>
                <counts group_id="E4" events="179" subjects_affected="131" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="583" subjects_affected="412" subjects_at_risk="1479"/>
                <counts group_id="E2" events="1017" subjects_affected="589" subjects_at_risk="1462"/>
                <counts group_id="E3" events="131" subjects_affected="106" subjects_at_risk="721"/>
                <counts group_id="E4" events="411" subjects_affected="255" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="126" subjects_affected="119" subjects_at_risk="1479"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1462"/>
                <counts group_id="E3" events="54" subjects_affected="47" subjects_at_risk="721"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="162" subjects_affected="147" subjects_at_risk="1479"/>
                <counts group_id="E2" events="436" subjects_affected="307" subjects_at_risk="1462"/>
                <counts group_id="E3" events="66" subjects_affected="57" subjects_at_risk="721"/>
                <counts group_id="E4" events="254" subjects_affected="172" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

